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ABSTRACT 
 
Lantz C. Mackey: The Role of !(1,3)-Fucosylated Glycans in Homeostatic 
Immunity, Granulopoiesis, and Mucosal Injury. 
(Under the direction of Jonathon W. Homeister)  
 The mechanisms that control granulopoiesis are poorly understood. 
Mice deficient in !(1,3)-fucosyltransferases (FUT) 4 and 7 (Fut-/-) lack 
selectin ligand activity and selectin-dependent leukocyte trafficking, and 
have a marked neutrophilia compared to WT mice. These studies utilize 
mouse models to examine the mechanisms that account for enhanced 
granulopoiesis in Fut-/- mice and how they alter the pathogenesis of 
colitis.  The results show that Fut-/- mice have elevated circulating IL-17 
and G-CSF concentrations, increased prevalence of IL-17-producing cells, 
and a marked neutrophilia compared to WT mice.  Analysis of selectin-
deficient mice showed that loss of all three selectins (E-,L-, and P-) 
induced the neutrophilia and enhanced IL-17 production, similar to Fut-/- 
mice.  These results suggest that loss of Fut-dependent selectin-mediated 
leukocyte trafficking alters granulopoiesis by modulating a previously 
proposed IL-17-dependnent granulopoietic regulatory loop. 
 Experiments using bone marrow transplants, adoptive neutrophil 
transfer, and myeloid-specific alteration of FUT7 expression revealed that 
 IV 
BM-derived myeloid cell trafficking is primarily responsible for regulating 
granulopoiesis.  In vitro analysis of BM-derived and tissue resident 
phagocyte populations reveal no defect in phagocytosis or IL-23 
production in Fut-/- mice. Together these results suggest Fut-dependent 
selectin-mediated myeloid cell trafficking, not tissue phagocyte function, 
regulates granulopoiesis.  
 DSS-induced murine colitis is largely dependent on the innate 
immune system and is exacerbated by elevated IL-17.  Compared to WT, 
colitis in Fut-/- mice was more severe, determined by weight loss, occult 
bleeding, and histology.  The role of Tcell-derived IL-17 in the 
development of colitis was examined using Rag1-/-/Fut-/- deficient mice.  
Absence of Tcells and Bcells did not alter disease severity in Fut-/- mice.   
 The results from these studies highlight the importance of Fut-
dependent leukocyte trafficking of BM derived myeloid cells in regulating 
IL-17-dependent granulopoiesis and modulating disease severity in DSS-
colitis.  Taken together these studies demonstrate that leukocyte 
trafficking is required to maintain homeostatic immunity, and that 
disruption can lead to significant alterations in the inflammatory state.  
 
 
 
 
 V 
 
 
 
 
 
 
DEDICATION 
I would never have been able to finish this project without the love and 
support of my family and friends, especially my wife Laura, and my 
children Lantz and Ashleigh. 
 
 
 
 
 
 
 
  
 VI 
 
 
 
TABLE OF CONTENTS 
LIST OF TABLES ..................................................................... X 
LIST OF FIGURES ................................................................. XI 
LIST OF ABBREVIATIONS .................................................. XIII 
Chapter 1 – Introduction ........................................................ 1 
1.1 Fucosyltransferases ............................................................. 1 
1.2 Selectins ............................................................................ 2 
1.3 Granulopoiesis .................................................................... 3 
1.4 Modulation of Granulopoiesis by Leukocyte Trafficking ............. 5 
1.5 IL-23 Production and Effector Function ................................... 6 
1.6 IL-17 Production and Effector Function ................................... 7 
1.7 G-CSF Production and Effector Function ................................. 8 
1.8 Emergency Granulopoiesis ................................................... 9 
1.9 Tissue Resident Macrophage Revolution ................................ 11 
1.10 DSS-Induced Colitis .......................................................... 14 
1.11 Significance ..................................................................... 16 
1.12 Figures and Tables ........................................................... 17 
Chapter 2 – Methods ............................................................ 22 
2.1 Mice ................................................................................. 22 
2.2 Euthanasia ........................................................................ 23 
2.3 Tissue Isolation ................................................................. 23 
 VII 
2.4 Blood Collection ................................................................. 23 
2.5 Complete Blood Counts ....................................................... 24 
2.6 Red Blood Cell Lysis ........................................................... 24 
2.7 Plasma Isolation ................................................................ 24 
2.8 Bio-Plex Cytokine Analysis .................................................. 25 
2.9 IL-23 ELISA ...................................................................... 26 
2.10 Mononuclear Cell Isolation ................................................. 26 
2.11 In Vitro Stimulation of Leukocytes ...................................... 27 
2.12 Flow Cytometry ............................................................... 27 
2.13 Messenger RNA Isolation ................................................... 28 
2.14 cDNA Synthesis ............................................................... 29 
2.15 Quantitative Polymerase Chain Reaction .............................. 29 
2.16 CD4 Tcell Isolation ........................................................... 30 
2.17 In Vitro Th17 Differentiation .............................................. 31 
2.18 Neutrophil Depletion ......................................................... 31 
2.19 In Vivo Endotoxemia ........................................................ 32 
2.20 Bone Marrow Isolation ...................................................... 32 
2.21 Irradiation ....................................................................... 32 
2.22 Bone Marrow Transplant ................................................... 33 
2.23 Peripheral Blood Neutrophil Isolation .................................. 33 
2.24 Neutrophil Fluorescent Labeling .......................................... 34 
2.25 Adoptive Neutrophil Transfer ............................................. 34 
2.26 Primary Kupffer Cell Isolation ............................................. 35 
2.27 BM-MC/BM-DC In Vitro Differentiation ................................. 35 
 VIII 
2.28 In Vitro Phagocytic Rate Assay ........................................... 36 
2.29 In Vitro Efferocytosis Assay ............................................... 37 
2.30 DSS-Induced Colitis .......................................................... 37 
2.31 Preparation of Colon for Histology ...................................... 38 
2.32 H&E Staining ................................................................... 38 
2.33 Histologic Scoring of Colon Sections .................................... 39 
2.34 Statistical Analysis ........................................................... 40 
Chapter 3 – Results .............................................................. 41 
3.1 Characterization of the Immune Response  
      in Fut-/- Mice ................................................................... 41 
3.1.1 Leukocyte Counts ............................................................ 41 
3.1.2 Fut-Dependent Alterations of Circulating Cytokine Levels ...... 42 
3.1.3 Expansion of IL-17 Producing Leukocyte  
        Populations in Fut-/- Mice .................................................. 44 
3.1.4 Fut-Dependent IL-17 Expansion and Neutrophilia 
        are Selectin Dependent .................................................... 47 
3.2 a(1,3)-Fucosyltransferase-Dependent  
        Alteration of Granulopoiesis ......................................... 48 
3.2.1 In Vivo Manipulation of Granulopoiesis ............................... 49 
3.2.2 !(1,3)Fucosylated Glycans on Myeloid Cells  
        Regulate Granulopoiesis ................................................... 50 
3.2.3 Tcells Are Not Required for Fut-Dependent  
        Alterations in Granulopoiesis ............................................. 52 
3.2.4 Bone Marrow-Derived Cells Are Responsible 
 IX 
        for Neutrophilia and IL-17 Expansion in Fut-/- Mice ............... 53 
3.2.5 Neutrophil Trafficking to Tissue Resident  
         Macrophages Regulates Granulopoiesis .............................. 56 
3.2.6 Fut-/- Phagocytes Have No Defect in  
        Phagocytic Rate, IL-23 Expression, or IL-23 Production ......... 57 
3.2.7 Efferocytosis Does Not Suppress IL-23 Expression  
         or Production ................................................................. 59 
3.3 Loss of !(1,3)Fucosylated Glycans Increases  
      the Severity of DSS-Induced Colitis ................................ 61 
3.3.1 Ten Day Time Point ......................................................... 62 
3.3.2 Eight Day Time Point ....................................................... 62 
3.3.3 Five Day Time Point ......................................................... 64 
3.4 Tables and Figures ............................................................. 66 
Chapter 4 – Discussion ......................................................... 84 
4.1 Summary of Main Findings .................................................. 84 
4.2 Considerations for the Manipulation of Leukocyte Trafficking .... 86 
4.3 Considerations for Our Understanding of the Regulation of       
Granulopoiesis .................................................................. 88 
4.4 Considerations for Leukocyte Adhesion Deficiency Type II ....... 90 
4.5 Understanding the Pathogenesis of Mucosal Injury in Colitis ..... 91 
4.6 Tables and Figures ............................................................. 93 
References ........................................................................... 94 
 
 
 
 X 
List of Tables 
 
Table 1.1 TRM Independence From the Bone Marrow .................... 20 
Table 1.2 Locations and Known Functions of TRMs ....................... 21 
Table 3.1 Alterations in Circulating Cytokine Levels ...................... 66 
Table 3.2 Cytokine Alterations in Unstimulated Fut-/- Mice ............. 67 
Table 3.3 Cytokine Alterations in LPS Stimulated Fut-/- Mice .......... 68 
Table 3.4 Summary of Leukocyte Trafficking Abilities ................... 74 
 
 
 
 
 
 
  
 XI 
List of Figures 
 
Figure 1.1 Fucosyltransferases in Mammals ................................. 17 
Figure 1.2 Proposed Density-Dependent Feedback  
                Loop that Regulates Granulopoiesis ............................ 18 
Figure 1.3 Emergency Granulopoiesis ......................................... 19 
Figure 3.1 Leukocyte Counts in Fut-/- Mice .................................. 65 
Figure 3.2 Enhanced IL-17 Production in Fut-/- Mice ...................... 69 
Figure 3.3 Enhanced IL-17 Production is Not Due  
                to Altered Tcell Differentiation ................................... 70 
Figure 3.4 Fut-Dependent Neutrophil and IL-17  
                production are Selectin-Dependent ............................. 71 
Figure 3.5 In Vivo Manipulation of Granulopoiesis ........................ 72 
Figure 3.6 Myeloid Cell Trafficking is Required for Maintenance  
                of Granulopoiesis and IL-17 Production ....................... 73 
Figure 3.7 Lymphoid Cells Not Required for  
                Fut-Dependent Neutrophilia ....................................... 75 
Figure 3.8 Transfer of Fut-/- BM into Lethally Irradiated 
               WT Mice Reconstitutes the Neutrophilia and  
               IL-17-Producing Cell Expansion in Fut-/- Mice ................ 76 
Figure 3.9 Transplantation of WT BM into Lethally Irradiated 
                Fut-/- Mice Restores WT Neutrophil  
                and IL-17-Producing Cell Counts ................................ 77 
Figure 3.10 Neutrophil Trafficking to the Liver  
 XII 
                 Regulates Granulopoiesis ......................................... 78 
Figure 3.11 Loss of Fut Activity Does Not Inhibit Macrophage  
                 Phagocytosis, Il-23 Expression or IL-23 Production ...... 79 
Figure 3.12 Efferocytosis Alone is Inadequate to  
                 Suppress IL-23 Expression or Production .................... 80 
Figure 3.13 Ten Day Time point: Fut-/- Mice Develop More  
                 Severe Colitis then WT Mice ..................................... 81 
Figure 3.14 Eight Day Time point: Rag1-/- and Fut-/- Mice  
                  Develop Severe Colitis ............................................ 82 
Figure 3.15 Five Day Time point: Fut-/- Mice Develop More  
                  Severe Colitis then WT mice. ................................... 83 
 
  
 XIII 
List of Abbreviations 
 
BM: Bone Marrow 
BM-MC: Bone Marrow Derived Macrophage 
BM-DC: Bone Marrow Derived Dendritic Cell 
pKC: Primary Kupffer Cell 
ILC: Innate Lymphoid Cell 
NKT: Natural Killer Tcell 
IL-: Interleukin- 
Fut: Fucosyltransferase 
EG: Emergency Granulopoiesis 
RPM: rotations per minute 
PBS: Phosphate Buffered Saline 
HBSS: Hanks Balanced Salt Solution 
qPCR: Quantitative Polymerase Chain Reaction 
mRNA: messenger RNA 
cDNA:  
n: Number 
Fut-/-: Fut4 and Fut7 Deficient Mice 
DSS: Dextran Sulphate Sodium 
 
! "!
  
 
 
 
Chapter 1 – Background and Introduction 
 
1.1 Fucosyltransferases 
The Fucosyltransferases (FUTs) are a family of glycosylating 
enzymes found in the Golgi that are responsible for catalyzing the 
addition of a fucose moiety to a protein or glycan[1].  To date there have 
been 12 distinct fucosyltransferases identified in humans with various 
substrate specificities and tissue expression patterns[2-4].  Of the 12 
FUTs identified in humans, nine murine homologs have been identified 
with similar sequence, structure and function to human FUTs[4].  
FUTs are classified by the manner in which they link the fucose 
moiety to the developing glycan.  FUTs 1 and 2 catalyze the addition of a 
fucose in !(1,2) linkage to a glycan chain and are responsible for 
synthesis of the blood group antigens in both humans and mice (Figure 
1.1)[2, 4].  FUTs 3, 4, 5, 6, 7, 9, and 11 catalyze the addition of a fucose 
using an !(1,3) linkage.  In mice FUT 3 is a pseudogene with no known 
function, and FUTs 5 and 6 have not been identified[2].  FUTs 4 and 7 are 
expressed in myeloid cells and are responsible for the formation of sialyl 
Lewis x, which is a component of all selectin ligands and is required for 
high affinity selectin binding[1, 7-9].  FUT 9 has been shown to be 
! #!
expressed predominately in the brain, skin and at low levels in peripheral 
blood leukocytes and is involved in the production of the Lewis x and 
Lewis y antigens[2, 3].  FUTs 10 and 11 have been identified but to date 
their functions and specificity remain unclear[2].  FUT 8 utilizes an !(1,6) 
linkage to fucosylate the µ heavy chain of the B-cell receptor and is 
required for proper B-cell development[2, 3].   PoFUT 1 is unique, in that 
it catalyzes the addition of an O-linked fucose directly to a peptide chain.  
PoFUT 1 has been shown to be involved in fucosylation of Notch ligands, 
which are integral to controlling thymocyte development[2, 4, 10]. 
Fut4 and Fut7 are of particular importance in regards to leukocyte 
trafficking.  As stated above, these enzymes are widely expressed in 
leukocytes and are responsible for the formation of sialyl Lewis x on the 
selectin ligand that is required in part for recognition by the carbohydrate 
binding domain on the selectin.   Mice deficient in FUT4 and FUT7 (Fut-/-) 
have been shown to have a severe selectin-dependent leukocyte 
trafficking deficiency[1, 8, 9].  
 
1.2 Selectins 
The selectins are a family of adhesion molecules that mediate 
leukocyte rolling.  Selectin recognition of, and binding to, their ligands is 
a crucial initial step in leukocyte trafficking to sites of infection and 
inflammation, and lymphocyte homing to secondary lymphoid organs.  P- 
! $!
and E- selectins are expressed on the activated endothelium and interact 
with their ligands (i.e. P-Selectin Glycoprotein Ligand -1, PSGL-1) 
expressed on the cell surface of circulating leukocytes, and are 
responsible for the initial stages of leukocyte extravasation[1, 7-9]. L-
selectin is expressed on leukocytes and is required for lymphocyte 
homing to peripheral lymph nodes via the high endothelial venules[7].  
Studies have shown that selectins and their ligands are post-
translationally glycosylated. During glycosylation of selectin ligands, FUT4 
and FUT7 catalyze the addition of a fucose moiety to the glycan chain 
completing the formation of sialyl Lewis x (sLex), which is essential for 
the high affinity interactions between selectins and their ligands[1, 2, 9]. 
Mice doubly deficient in FUT4 and FUT7 are unable to produce functional 
E-, P-, or L-selectin ligands. Studies using these mice have demonstrated 
that the loss of selectin ligand activity leads to reduced leukocyte 
migration, altered inflammatory responses, a pro-thrombotic state, and a 
pronounced leukocytosis with neutrophilia[1, 2, 4, 7-9].  
 
1.3 Granulopoiesis 
 Neutrophils are a phagocytic cell of the innate immune system.  
These cells are found in large numbers in peripheral blood and 
tissues[11-13].  It is believed that neutrophils have a short half-life 
ranging from 12 - 36 hours in circulation, after which they traffic into 
! %!
peripheral tissues where they are phagocytosed and degraded[14-17].  
Under inflammatory conditions neutrophils are rapidly recruited to sites of 
infection and injury where they phagocytose bacteria and cellular debris, 
release various proinflammatory mediators and antibacterial peptides 
(perforin & granzyme), and secrete matrix-modifying enzymes 
(MMP8)[12, 13].  These cells are considered the ‘front line’ in the immune 
system, and patients with reduced neutrophil counts are at serious risk 
for infection[12, 18, 19]. Due to the neutrophil’s short lifespan yet vital 
function, they must be constantly produced to ensure an adequate supply 
in the blood stream.  Granulopoiesis, or the process of neutrophil 
differentiation and maturation, occurs in the bone marrow as 
hematopoietic stem cells undergo several differentiation steps until 
terminal differentiation into mature neutrophils[14, 20].   
 Despite the importance of granulopoiesis, the detailed regulatory 
network modulating this process has not been fully described.  However, 
recent studies have demonstrated that impaired leukocyte trafficking can 
drastically alter granulopoiesis[11, 12, 14, 15, 17, 20].  An elegant series 
of experiments led to the proposal of a feedback loop that regulates 
granulopoiesis (Figure 1.2)[20].  This model suggests that the extra-
vascular neutrophils in peripheral tissues undergo apoptosis and are 
taken up by macrophages and dendritic cells.  This efferocytosis 
(phagocytosis of an apoptotic neutrophil) reduces IL-23 production by 
! &!
resident macrophages and dendritic cells.  IL-23 stimulates IL-17 
production by various leukocyte populations, which in turn increases 
Granulocyte-Colony Stimulating Factor (G-CSF) production[20].  Changes 
in G-CSF production control the rate at which neutrophils differentiate, 
mature, and are released from the bone marrow. Alteration of IL-23, IL-
17, or G-CSF production or signaling can severely alter granulopoiesis 
and thereby the ability of the innate immune system to respond to 
infection or tissue damage[19-24].   
 
1.4 Modulation of Granulopoiesis by Leukocyte Trafficking 
 The ability of leukocytes to traffic out of the vasculature and into 
the periphery to patrol for tissue damage or infection is a key component 
of the innate immune system[1, 9, 20].  Blocking proper trafficking of 
neutrophils, macrophages, and/or dendritic cells leaves animals with an 
elevated risk for infection[11, 13, 18, 19, 25]. Impairment of neutrophil 
trafficking reduces the number of neutrophils that enter the tissue, 
phagocytose cell debris or bacteria, and undergo apoptosis[26].  
Efferocytosis has been shown to result in potent anti-inflammatory 
effects[27-34].   For example, efferocytosis induces IL-10 and TGF-" 
production, reduces IL-23 and TNF-! production, and increases alpha 
defensin levels[27, 28, 35, 36].  However, the underlying mechanisms 
leading to these responses remain unclear.  
! '!
 During efferocytosis, the key response that modulates 
granulopoiesis is the reduction or cessation of IL-23 production by 
macrophages and dendritic cells[11, 17, 20, 27, 36-39].  In the case of a 
neutrophil trafficking deficiency (as seen in mice lacking FUT4 and FUT7) 
efferocytosis in the periphery should be reduced, resulting in enhanced 
IL-23 production, leading to elevated rates of granulopoiesis.   
  
1.5 IL-23 Production and Effector Function 
 IL-23 is a member of the IL-12 family of cytokines[36].  It is a 
heterodimeric cytokine made up of a conserved p40 subunit (shared with 
IL-12) and a unique p19 subunit[36].   Production of IL-23 can be 
induced following Toll-Like Receptor (TLR) recognition of bacterial 
products (i.e. LPS or peptidoglycan), Dectin-1 receptor recognition of 
fungal "-glucans, or via CD40/CD40L interaction[36, 38].  Secreted IL-23 
will bind to the IL-23 receptor that is made up of an IL-12R"1 subunit 
(which recognizes the p40 domain) and the IL-23 subunit (which 
recognizes the p19 domain)[36, 40, 41].  IL-23R expression is controlled 
by the transcription factors ROR! and ROR#t which are only expressed in 
specific lymphoid cells: Th17 Tcells, #$ Tcells, some Natural Killer Tcells 
(NKT cells), and Innate Lymphoid cells (ILCs)[39, 41, 42].  Binding of IL-
23 to IL-23R causes the activation of an intracellular signaling cascade 
through Janus associated kinase (Jak)/ signal transducer activator of 
! (!
transcription (STAT) signaling.   Jak2 and tyrosine kinase 2 (Tyk2) will 
phosphorylate the IL-23R complex, creating binding sites for STATs 1, 3, 
4, and 5 which become phosphorylated, dimerize and translocate to the 
nucleus to drive the transcription of STAT-responsive genes[39, 42, 43].  
In general, IL-23 signaling induces a proinflammatory response, however 
the precise nature of the response depends on the specific cell type that 
has been activated[41, 44, 45].  In lymphocytes, STAT3 is preferentially 
phosphorylated while STAT4 and STAT5 are weakly phosphorylated[42, 
46].  This results in activation of an IL-17-producing phenotype in subsets 
of lymphocytes.  
 
1.6 IL-17 Production and Effector Function 
 IL-17 is a recently identified cytokine that has been implicated in 
inflammatory and autoimmune diseases ranging from asthma and 
multiple sclerosis, to defense against fungal infections[10, 47].  IL-17 
production by Th17 Tcells, #$ Tcells, NKT cells, and ILCs is induced by IL-
23 stimulation of the IL-23R, or by the combined stimulation of IL-6 and 
TGF-"[20, 41, 43, 48, 49].  Stimulation of these receptors results in the 
activation of Jak2, which phosphorylates STAT3.  After activation by 
phosphorylation, STAT3 forms a heterodimer and translocates to the 
nucleus to drive the transcription of the orphan nuclear receptor ROR#t, 
which is responsible for initiating the transcription of IL-17a, IL-17f, IL-
! )!
22, and IL-23R[10, 22, 47, 50, 51].  While ROR#t has been shown to be 
the key transcription factor responsible for controlling IL-17 production, it 
does interact with several enhancer proteins (NFAT, Batf, c-Maf, AhR, and 
RUNX1) that amplify IL-17 production[10, 42].  The ability of IL-17-
producing cells to upregulate IL-23R allows these cells to perpetuate an 
IL-17 response, in an autocrine and paracrine manner.  
 After secretion, IL-17 binds to the IL-17RA/IL-17RC complex, 
causing the phosphorylation of Act1[10, 42]. The kinases down stream of 
Act1 that are involved in transducing the IL-17 signal have yet to be fully 
elucidated, however it is clear that IL-17 can activate the NF-%B, MapK, 
and C/EBP!/" signaling pathways[50-53].  While IL-17R signaling can 
stimulate the expression of many target genes, the most relevant for 
granulopoiesis is C/EBP-dependent expression of G-CSF[22, 37, 39, 51].  
 
1.7 G-CSF Production and Effector Function 
 G-CSF is a key growth factor that controls the survival, 
proliferation, and maturation of neutrophils[6, 14].  G-CSF production can 
be induced in stromal cells following stimulation with IL-17, LPS, TNF!, or 
IL-1" [25].  Activated C/EBP" and NF-%B p65 binds to the G-CSF 
promoter to drive its transcription[25, 54, 55]. After secretion, G-CSF 
binds to the G-CSFR, which is expressed on myeloid progenitors, 
endothelial cells, cardiomyocytes, granulocytes, and some monocytes.  
! *!
The G-CSFR signals by activating Jak1 and Jak2, creating binding sites for 
STAT1, STAT3, and ERK1/2[25, 54, 55].  While STAT3 is thought to be 
responsible for stimulating granulocyte maturation and release under 
normal conditions, experiments revealed a pronounced neutrophilia in 
STAT3-deficient mice instead of a neutrophil deficiency[25, 55].  The 
investigators hypothesized that in the absence of STAT3, suppressor of 
cytokine signaling (SOCS) 3, which inhibits STAT signaling, remains 
inactive allowing STAT1 and ERK1/2 to continuously stimulate neutrophil 
release from the bone marrow [55].  G-CSFR signaling activates a diverse 
set of target genes responsible for accelerating cell cycle progression and 
proliferation (Cyclin D3), enhancing neutrophil maturation (c-fos, IRF-1, 
PU.1), enhancing neutrophil effector function (Fc#II/III , Mac1), and 
promoting neutrophil survival[11, 14-16, 25, 54-56]. 
  
1.8 Emergency Granulopoiesis 
 In addition to steady-state regulated homeostatic granulopoiesis, 
the body must be able to rapidly respond to infectious stimuli by greatly 
expanding production and release of neutrophils.   This process of rapid 
de novo production of neutrophils is called emergency granulopoiesis 
(EG)[6, 25].  While the result of EG is similar to normal granulopoiesis, it 
is thought to have distinct separate signaling mechanisms that override 
! "+!
bone marrow production of other cell types, and focus on the production 
of neutrophils[57, 58].   
 Activation of EG can occur directly or indirectly.  Direct activation 
occurs when bacterial components (LPS, PAMPS) are recognized directly 
by the hematopoietic stem cells (HSCs)[59].  In the case of LPS 
activation of TLR4, myd88 is phosphorylated and activates NF-%B and AP-
1 signaling, promoting proliferation of HSCs and IL-6 production[60, 61].  
These factors promote granulopoiesis and suppress lymphopoiesis[6].   
Indirect activation of EG occurs when bacterial products are recognized by 
pattern recognition receptors (PRRs) on peripheral leukocytes or certain 
non-hematopoietic cells (endothelial cells)[62, 63].  Activation of these 
cells causes the production of various cytokines, including IL-6 and G-
CSF.  Under infectious conditions levels of G-CSF are significantly 
elevated resulting in increased G-CSFR signaling (Figure 1.3.) [6, 25, 58, 
64-66].   
 Regardless of which method stimulates EG, they both result in the 
activation of C/EBP"[57, 65, 67].  As discussed above, steady-state 
granulopoiesis requires G-CSF signaling through C/EBP!.  In EG, hyper-
activation of G-CSFR causes a STAT3-dependent switch from C/EBP! to 
C/EBP"[6, 58, 65, 68, 69].  This switch promotes the rapid proliferation, 
maturation, and subsequent release of neutrophils into the blood stream. 
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1.9 The Tissue Resident Macrophage Revolution 
 Macrophages are specialized immune cells capable of phagocytosing 
infectious agents and cell debris, secreting cytokines and inflammatory 
mediators, and antigen presentation[70].  Macrophage function and 
phenotype can vary greatly depending on its location within the body and 
activating stimulus[5, 70-74].   It has long been thought, that 
macrophages differentiate from bone marrow-derived monocytes, and 
that the cytokine cues present at the site of activation determined the 
macrophages function[75-77].  While there are bone marrow-derived 
circulating monocytes which do behave in this fashion, recent studies 
have clearly demonstrated that there are distinct populations of tissue 
resident macrophages (TRMs) that are capable of maintenance and self 
renewal independent of the bone marrow[5, 70, 72, 73, 77-80].  
 One of the first reports to demonstrate these findings was published 
by Schulz et al[78].  Their studies utilized a sophisticated cell lineage 
tracing system and bone marrow reconstitution to assess whether TRMs 
were dependent on the bone marrow.  Their findings, summarized in 
Table 1.1, demonstrate that some pools of TRMs are maintained 
completely independent of the bone marrow[78].  Langerhans and 
Kupffer cells isolated from chimeric mice were 100% host-derived[78].  
Splenic and pancreatic macrophages were found to be 90% host-derived 
and 10% donor-derived[78].  Alveolar and kidney macrophages were 
! "#!
found to be heterogeneous with 50% being donor-derived and 50% being 
host-derived[78].  These findings forced scientists to re-evaluate the 
interpretation of decades of findings regarding macrophage function in 
the pathogenesis of disease.   
 In addition to TRMs being independent of the bone marrow, many 
studies have shown that TRM populations are established during 
embryonic development.   Langerhans cells, microglia, Kupffer cells, 
pancreatic macrophages, alveolar macrophages, and splenic red pulp 
macrophages are derived from the embryonic yolk sac[5, 70, 72, 75, 78-
80].  It is worth noting that during embryonic development hematopoiesis 
occurs within the fetal liver, rather then in the bone marrow.  During the 
transition period from fetal liver to bone marrow hematopoiesis, the 
remaining TRM populations are seeded into their respective tissues (Table 
1.2)[5].  
 While many tissues have TRMs, some tissues do rely on the classic 
bone marrow-derived monocytes to infiltrate into the tissues and 
maintain immune surveillance.  The gut is one example of a tissue that 
appears to rely exclusively on monocyte-derived macrophages to 
maintain normal function[30, 70, 71, 77, 81].  However, to date most 
tissues have been shown to maintain a TRM population that is 
responsible, at least in part, for normal function. 
! "$!
 TRMs are specialized to help maintain proper function of diverse 
tissue types.  However, under infectious or inflammatory conditions, bone 
marrow-derived CD11chi monocyte-derived macrophages respond to 
chemotactic gradients and enter the inflamed or damaged tissues[30, 82, 
83].  These inflammatory macrophages specialize in phagocytosing 
infectious agents and cellular debris and aid in priming the adaptive 
immune system to respond to chronic infections.  During the resolution of 
inflammation, TRMs exert an anti-inflammatory effect, reducing the 
number of inflammatory macrophages infiltrating into the tissue[5, 83].   
 The discovery of TRM independence from the BM, has severely 
complicated our understanding of the regulation of granulopoiesis.  One 
of the main questions researchers have asked is ‘where are the majority 
of neutrophils being cleared to maintain steady state granulopoiesis?’.  
Now that several distinct populations of TRM have been shown to be 
independent and functionally distinct from each other and the bone 
marrow, it becomes more difficult to identify which populations of TRMs 
contribute to the clearance of apoptotic neutrophils and the regulation of 
granulopoiesis.  Further research needs to be done to adequately address 
this question.  
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1.10 DSS-Induced Colitis 
 Inflammatory bowel disease (IBD) is a complex disease comprised 
of Crohn’s disease and ulcerative colitis.   In the developed world, these 
chronic inflammatory diseases of the intestine affect 1 out of 200 
people[84].  Ulcerative colitis is characterized by loss of the intestinal 
mucosa starting at the rectum and extending continuously proximally.  
The destruction to the mucosa leaves an open mucosal wound or ulcer, 
allowing the bacterial microflora to establish opportunistic infections and 
maintain a chronic inflammatory state[48, 85].   Crohn’s disease causes 
multifocal inflammation in non-continuous sections of the gastrointestinal 
tract.  The inflammation in these lesions is transmural, affecting the 
entire thickness of the intestinal wall, causing significant fibrosis and 
thickening of the wall[48, 85].  As the disease progresses strictures can 
form and lead to obstructions of the bowel.     
 Due to the high incidence of IBD, lack of effective treatments, and 
the poor understanding of the pathogenesis of the disease, the use of 
animal models are needed to help identify the mechanisms underlying the 
pathogenesis of disease.  Several animal models of colitis are currently 
used, however dextran sulphate sodium (DSS)-induced colitis is by far 
the most widely used[84-88].  This chemically-induced model of colitis is 
reproducible, simple to perform, and has histologic features that closely 
match those found in human UC [84-88].DSS is thought to be toxic to the 
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gut epithelial cells and disrupts the tight junctions between the epithelial 
cells in the mucosa.  As gaps begin to form, bacterial products invade into 
the tissue and drive inflammation[48, 81, 84, 87, 88]. 
Initial colitis in this model is dependent on monocytes and 
granulocytes, as Rag1-/- mice that lack lymphocytes develop severe 
colitis[81, 86-89]. As the disease progresses the inflammatory innate 
immune cells invade into the mucosa and submucosa, causing the loss of 
crypts and eventually destruction of the entire epithelial layer[48, 85, 
86].  In addition to the acute granulocyte-dependent colitis, recurring 
rounds of DSS administration followed by 14-28 days of water 
administration for recovery allow researchers to study the adaptive 
immune response in colitis as well as the mechanisms involved in crypt 
regeneration[44, 81, 90].   
 Studies have shown that the induction of colitis causes elevations in 
proinflammatory cytokines such as IL-1!, IL-1", IL-6, IL-17, G-CSF, and 
MIP-1"[44, 48, 81, 85, 90-92].  These inflammatory mediators drive 
inflammation and help to induce the expression of chemokines such as 
Eotaxin and CCL2 that will enhance granulocyte recruitment to the 
inflamed colon.   
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1.11 Significance 
 Leukocyte trafficking plays a vital role in the immune system.  The 
complex cell-cell interactions that mediate cellular adhesion, migration, 
and homing have been extensively studied.  The role of selectins in 
leukocyte tethering and rolling during the process of trans-endothelial 
migration has been well characterized.  Fut-/- mice lack functional 
selectin-ligand activity, and as expected have a mark selectin-dependent 
leukocyte trafficking deficiency.  Fut-/- mice also have a leukocytosis 
primarily comprised of a neutrophilia.  The mechanisms involved in the 
Fut-dependent neutrophilia are not known.   Additionally, the effect of the 
loss of Fut4 and Fut7 activity on the immune response is unknown.  Our 
studies seek to determine the underlying mechanisms responsible for the 
neutrophilia in Fut-/- mice, and to assess the role of !(1,3)-fucosylation on 
leukocytes on maintenance of homeostatic immunity and the 
pathogenesis mucosal injury.  Bone marrow transplantation will be 
preformed to determine the relative contribution of bone marrow derived 
cells to maintaining the neutrophilia in Fut-/- mice.  Assessment of 
transgenic mouse strains with myeloid specific expression or deletion of 
FUT7, enable us to determine the role of myeloid cell trafficking in 
regulating granulopoiesis.  Additionally these mouse lines will be 
subjected to DSS-induced colitis to determine the effect the loss of Fut-
dependent trafficking has on the pathogenesis of colitis. 
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% Host-Derived  % Donor-Derived 
Skin 100 0 
Liver 99 1 
Spleen  90 10 
Pancreas 91 9 
Lung 45 55 
Kidney 44 56 
Table 1.1 - TRM independence from the Bone Marrow 
These results show the percentage of F4/80+ cells isolated 
from the organs of Bone Marrow Transplant mice were host 
derived or donor derived. 
 
Data from Schulz et al [78]. 
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Tissue Cell Type Function 
Adipose Tissue Adipose-associated 
macrophages 
Control Insulin Sensitivity 
and thermogenesis. 
Blood Ly-6Clo monocytes Intra-vascular TRM, clear 
endothelial cell debris. 
Bone Osteoclasts 
 
 
 
Bone Marrow 
Macrophages 
Resorb bone by disrupting 
matrix. 
 
 
Support hematopoiesis 
and maintain stem cells in 
their niches.  Self-
renewing population. 
Central Nervous 
System 
Microglia 
 
 
 
 
Protect neurons, remove 
cellular debris, maintain 
immune surveillance.  
Derived from embryonic 
yolk-sac and maintained 
independent of BM. 
Gastrointestinal 
Tract 
Intestinal Macrophages Blood monocyte derived, 
maintain intestinal 
homeostasis and modulate 
immune response to 
commensal bacteria. 
Liver Kupffer Cells Maintained independently 
from BM.  Clear cell debris 
and infectious material 
from blood. 
Lung Alveolar Macrophage Clearance of inhaled 
pathogens and debris.  
Skin Langerhans Cells Present antigens to Tcells, 
yolk-sac derived.  
Maintained independently 
from BM. 
Spleen Red Pulp Macrophages Clear erythrocytes and 
metabolize iron.  Yolk-sac 
derived, maintained 
independent of BM. 
Table 1.2 - Locations and known functions of TRMs. Adopted from 
Davies et al.[5] 
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Chapter 2 – Methods and Protocols 
 
2.1 Mice 
 All mice were maintained in a specific pathogen free environment.  
Mice were housed in standard shoebox cages, with constant access to 
chow and water. All experiments were approved by the Institutional 
Animal Care and Use Committee (IACUC) at the University of North 
Carolina-Chapel Hill.  Animals had full access to husbandry and veterinary 
provided by DLAM.  In compliance with ethical standards, the fewest 
number of mice necessary were used for experiments.  Experimental 
protocols minimized animal pain and distress. 
 All mouse lines are on the C57bl/6J genetic background.  Fut4-/-, 
Fut7-/-, and Fut-/- mice were a gift from Dr. Lowe (University of Michigan) 
and have been propagated and maintained at our facility. WT and Rag1-/- 
mice were purchased from The Jackson Laboratory and bred in-house for 
experimental use.  To generate Rag1-/-/Fut-/- mice, Rag1-/- males were 
bred to Fut-/- females, progeny were then genotyped and crossed until 
the triple null Rag1-/-/Fut-/- mouse was obtained.  These mice were then 
bred and maintained as homozygous null for Rag1, Fut4, and Fut7.  ELP-/- 
and L-selectin-/- mice were a gift from Dr. Richard Hynes (MIT), and were 
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bred in-house for experimental use.    P- and E-Selectin-/- mice were a 
gift from Dr. Claire Doerschuk (UNC), and were provided as needed for 
experiments. 
 
2.2 Euthanasia 
 Mice were euthanized by asphyxiation in a CO2 chamber and death 
was ensured by cervical dislocation, exsanguination or lethal tissue 
harvest, in compliance with IACUC and DLAM regulations 
 
2.3 Tissue Isolation 
 After euthanasia animals were wetted with 70% ethanol to 
minimize bacterial contamination of isolated tissues.  Thoracotomy or 
laparotomy was performed, and the required organs (spleen, liver, lungs, 
colon, lymph nodes, heart) were harvested. 
 
2.4 Blood Collection 
   After euthanasia, the peritoneal cavity was opened and the 
intestines were reflected to the side, exposing the inferior vena cava.  
Blood was withdrawn from the IVC using a 25-gauge needle fitted to a 
1ml syringe filled with 70ul sodium citrate solution (Sigma) to prevent 
clotting.  Each adult mouse yielded 500-800ul of blood. 
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2.5 Complete Blood Counts 
 Complete Blood Counts (CBC) were determined in venous whole 
blood treated with EDTA, using an automated Heska Veterainry 
hematology analyzer, and appropriate species-specific software and 
parameters.  The automated cell counter provides the total leukocyte, 
granulocyte, monocyte, lymphocyte, hematocrit, and platelet counts for 
each sample.  Samples from animals were run in duplicate to ensure 
accuracy. 
 
2.6 Red Blood Cell Lysis 
 Red blood cell (RBC) lysis was performed using BD Pharm Lyse 
buffer according to manufacturer’s specifications.  In brief, the buffer is 
diluted into DI water 1:10 and incubated with blood sample (2 ml buffer 
for every 500 ul whole blood) for 10 minutes in the dark at room 
temperature, to lyse the RBCs.  The cells are then centrifuged at 300 x g 
for 5 min and resuspended in PBS.  This protocol was repeated if 
necessary.  
 
2.7 Plasma Isolation 
 Whole venous blood was collected as described above using sodium 
citrate as an anti-coagulant.  Samples were centrifuged for 20 min at 300 
x g with no brake.  The red cells pellet, and the leukocytes form a buffy 
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coat at the interface between RBC pellet and the plasma supernatant.  
The plasma was then carefully isolated with a pipette, avoiding the buffy 
coat. The samples were placed in labeled tubes and used directly for 
experiments or frozen at -80°C for subsequent analysis. 
 
2.8 Bio-Plex Cytokine Analysis 
 Circulating cytokine levels were quantitated using a 23-plex 
cytokine array (BIO-RAD).  Plasma was isolated as described above from 
untreated and LPS-injected WT and Fut-/- mice, and used immediately for 
the assay.  The assay was performed by the Advanced Analytics Core at 
UNC-CH according to the manufacturers instructions.  The assay plate 
was washed, 50 ul of pre-mixed beads were added to the wells, and the 
wells were washed 2x. 50 ul of samples, standards, or blanks were added 
to the beads in the well, and incubated shaking (850 rpm) overnight at 
room temperature.  The wells were then washed 3x, 25 ul of detection 
antibody was added to each well and incubated for 30 minutes at RT. 
Beads were then washed 3x, resuspended in 125 ul assay buffer and 
analyzed on a MAGPIX plate reader.  Florescence was measured and 
compared to the standard curve to determine the concentration of each 
cytokine in each sample.  
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2.9 IL-23 ELISA 
 IL-23 production by macrophage cultures was determined using an 
IL-23 Quantikine ELISA (R&D) according to manufacturers protocol.  
Supernatants were isolated from macrophage cultures, spun at 300 x g 
for 5 min to pellet cells and debris, and frozen at -80°C until the ELISA 
was performed.  The ELISA plate was blocked with assay diluent for 1 
hour at RT.  50ul of samples or standards were then incubated in the 
assay plate wells for 4 hours at RT.  The plate was washed 5x with wash 
buffer and incubated with 100uL of IL-23 antibody conjugate for 2 hours 
at RT. The plate was washed 5x, then incubated with 100uL substrate 
solution for 30 min at RT in the dark.  The reaction was stopped with 
100uL stop solution and the absorbance was determined at 450nm.  
Results were compared to a generated standard curve to determine the 
IL-23 concentration in each sample.  Samples were run in triplicate. 
 
2.10 Mononuclear Cell Isolation 
 Histopaque-1077 (Sigma) was used to isolate mononuclear cells 
from a cell suspension by density gradient centrifugation.  Histopaque-
1077 was carefully layered under the cell suspension, and centrifuged at 
300 x g for 30 minutes at RT with no brake.  After centrifugation the 
mononuclear cells are recovered from the gradient interface and 
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transferred to a new tube, resuspended with fresh media and washed 3x, 
then centrifuged for 5 minutes a 300 x g at 4°C and used in experiments.   
 
2.11 In Vitro Stimulation of Leukocyte Activation 
 Mononuclear cells from the spleen, bone marrow, blood or other 
tissues were isolated as described above and resuspended in RPMI with 
10% FBS and Penicillin/Streptomycin.  1x106 purified cells in 5ml media 
were then incubated with 10ul PMA/Ionomycin with Brefeldin A (BD) or in 
untreated culture media for 4 hours. PMA/Ionomycin activates leukocytes 
to induce cytokine production, and Brefeldin A inhibits vesicle transport to 
ensure that produced cytokines are not secreted.  After stimulation the 
cells are washed 3x by centrifugation at 300 x g for 5 min at 4°C, and 
resuspended in fresh culture media for analysis by flow cytometry. 
 
2.12 Flow Cytometry 
 Flow cytometry was used to rapidly identify cell populations and 
assess cytokine production.   1x106 unstimulated or stimulated (as 
described above) cells were plated into each well of a 96-well plate and 
washed 3x by centrifuging at 300 x g and resuspending the cells in Facs 
buffer (1x PBS, .5% BSA, 2 mM EDTA).  The cells were then incubated 
with 100 ul surface staining antibody cocktail (antibodies each at 1 
ug/mL) containing the desired cell linage-specific antibodies f
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4°C, protected from light.  Cells were then washed 3x as described 
above.  For intracellular cytokine (IC) staining, cells were fixed with 100 
uL fixation buffer (Biolegend) for 20 minutes in the dark, permeabilized 
by incubation with 100 uL perm/wash buffer (Biolegend) for 5 minutes, 
washed 3x by centrifuging the plate at 300 x g for 5 minutes, and then 
resuspending the cells in perm/wash buffer.  Cells were then incubated 
with 50 ul of IC antibody cocktail in perm/wash buffer (antibodies at 
2ug/mL) for 1 hour at 4°C, washed 3x, resuspended in Facs buffer, 
transferred to clean assay tubes, and analyzed using a Cyan Flow 
Cytometer (DAKO). 
 
2.13 Messenger RNA Isolation 
 Qiagen RNeasy kits were used to isolate mRNA from cultured cells 
or freshly harvested cells isolated from tissues.  5x106 cells were 
suspended in 600 ul RLT buffer and pipetted into a Qiashredder column 
and centrifuged at max speed for 2 min.  The cell lysates were then 
mixed with 600ul 70% ethanol, transferred to an mRNA isolation column, 
and spun at 9000 rpm for 20 seconds.  The flow through was discarded, 
and the column was washed once with RW1 buffer, and twice with RPE 
buffer.  The membrane was dried by spinning at max speed for 1 minute.  
mRNA was then eluted from the column with 50ul nuclease-free water.  
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mRNA concentrations were assessed using a nano-drop 
spectrophotometer, then stored at -80°C. 
 
2.14 cDNA Synthesis 
 mRNA was converted to cDNA using the SuperScriptase III kit 
(Invitrogen), according to the manufacturers protocol.  To convert 24 ul 
of mRNA to cDNA a primary mix was made by combining the 24 ul mRNA, 
3 ul dNTPs, 1.5 ul of oligo dTs, and 6 ul H2O.  The mix was heated to 
65°C for 5 minutes followed by 4°C for at least 2 minutes.  A secondary 
mix of 6 ul buffer, 6 ul DTT, 12 ul MgCl, 1.5ul superscriptatse, 1.5 ul 
RNaseout was added, and the reaction was heated at 50°C for 50 minutes 
followed by 85°C for 5 min.  To degrade the mRNA, 1.5 ul RNaseH was 
added and incubated at 37°C for 20 minutes.  After the reaction the cDNA 
was diluted to 5 ng/uL and stored at -20°C. 
 
2.15 Quantitative Polymerase Chain Reaction 
 To assess gene transcription, quantitative polymerase chain 
reaction (qPCR) was performed on cDNA samples prepared as described 
above.  Primers and probes for murine IL-23p19, IL-6, "-actin, fibrinogen, 
and IL-10 were purchased from Applied Biosystems.  A 20 ul reaction was 
used, containing 10 ul of Taqman universal mastermix II (ABI), 1 ul 
primer/probe, 4 ul cDNA (20ng), 5 ul H2O.  The reaction was run on an 
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ABI 7500 Fast machine.  The &&CT method was used to determine 
alterations in gene transcription between experimental groups, using "-
actin as the housekeeping gene. 
 
2.16 CD4 Tcell Isolation 
 Dynabeads Untouched CD4 Mouse Tcell isolation kit (Invitrogen) 
was used to isolate Tcells from freshly isolated splenocytes.  Beads were 
resuspended and 1 mL suspensions was added to tubes and placed onto 
the magnet for 1 minute to prewash.  The supernatant was discarded, the 
tube was removed from magnet, and the beads were resuspended in 1 
mL of isolation buffer.  Splenocytes were diluted to 1x108 cells per mL in 
isolation buffer, then 500 uL cell suspension was added to a clean tube 
containing 100 ul FBS and 100 ul antibody mixture for 20 minutes at 4°C.  
Cells were washed by adding 10 mL isolation buffer, then centrifuged at 
300 x g for 5 minutes at 4°C.  The cells were resuspended in 4 ml 
isolation buffer, and 1 mL prewashed beads were added and allowed to 
incubate for 20 minutes at RT.  Five mL isolation buffer was added and 
the solution was mixed to resuspended cells and beads.  One mL of the 
suspension is transferred to a new tube on the magnet for 2 minutes.  
Supernatant containing negatively isolated CD4 Tcells is collected in a 
new tube. The purity of the isolated cell suspension is confirmed by 
staining with CD4, and assessing percentage of CD4+ cells via flow 
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cytometry as described above. The sample purity was confirmed to be 
>90%. 
 
2.17 In Vitro Th17 Differentiation 
 Naïve CD4+ Tcells were subjected to an in vitro differentiation 
protocol first described by Ivanov et al. [47].  Tcells were plated into a 
12-well plate in RPMI medium with 10% FBS, pen/strep, !-CD28 (1 
ug/mL), !-CD3 (0.25 ug/mL), IL-23 (10 ng/mL), IL-6 (20 ng/mL), and 
TGF" (0.3 ng/mL) for 7 days at 37°C.  After differentiation, Tcells were 
stimulated with PMA/Ionomycin and assessed for IL-17 production via 
Flow cytometry as described above. 
 
2.18 Neutrophil Depletion  
 Eight to twelve week old male WT or Fut-/- mice were administered 
the neutrophil-specific Ly-6g (1A8) antibody (i.p.) to deplete circulating 
neutrophils.  WT mice received 1mg of antibody, Fut-/- mice were given 1 
mg, 9 mg, or an equal volume of PBS as control.  Blood samples were 
taken at 0, 12, 24, and 36 hours post injection and circulating neutrophil 
counts were assessed as described above. 
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2.19 In Vivo Endotoxemia 
 Eight to ten week old male WT or Fut-/- mice were injected i.p. with 
1 mg/kg of LPS (Sigma) in PBS.  Venous blood samples were obtained at 
0, 12, 24, 36, and 48 hours post injection and circulating neutrophil 
counts were assessed as described above. 
 
2.20 Bone Marrow Isolation 
 Bone marrow (BM) was isolated from the femur and tibia of 12 
week-old male mice.  Mice were euthanized and the femurs and tibias 
were harvested.  A 25-gauge needle attached to a 20 mL syringe filled 
with chilled RPMI was inserted into the end of the bone and the marrow 
was flushed out into a sterile pyrogen-free 50 ml conical tube. A wide 
mouth pipette was then used to break up the clumps of cells. The cells 
were then spun at 300 x g for 5 min at 4°C and resuspended in fresh 
media for subsequent experimental use. 
 
2.21 Irradiation 
 Six to eight week old male WT or Fut-/- were placed in a rodent 
irradiation pie container and irradiated with 9 gy or 12 gy of ionizing 
radiation in a XRAD 320 biological irradiator.  The mice were then 
transferred to sterile cages and given acidified water (pH 2.7) ad libitum 
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for 14 days.  Mouse weight and general health was monitored and 
recorded daily. 
 
2.22 Bone Marrow Transplant 
 WT or Fut-/- mice were irradiated as described above, and allowed 
to recover for 4 hours, during which time BM was isolated from WT or Fut-
/- mice.  Irradiated mice were anesthetized with isoflourine, and injected 
i.v. via the tail vein with 1x107 BM cells from either WT or Fut-/- mice.  
The injected mice were returned to sterile cages and given acidified water 
for 2 weeks.  Six weeks after transplant, the mice were euthanized, 
venous blood was harvested for CBC, and splenocytes were assessed for 
IL-17 production via flow cytometry as previously described. 
 
2.23 Peripheral Blood Neutrophil Isolation 
 Neutrophils were isolated from the venous blood of WT or Fut-/- 
mice as described above.  RBC’s were lysed as described above.  The 
remaining cell suspension was layered over histopaque-1077 and 
centrifuged at 300 x g for 30 minutes.  The neutrophil-enriched cell pellet 
was washed in Facs buffer, and pelleted again.  The neutrophils were then 
resuspended in RPMI with 10% FBS.  Flow cytometry was used to assess 
purity using a Ly-6G antibody.  Purity normally ranged from 75-85%. 
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2.24 Neutrophil Fluorescent Labeling 
 Isolated neutrophils were transferred into serum free RPMI media 
containing 5 uM CellTracker Dye (CMFDA or CMPTX) (Invitrogen) for 45 
minutes at 37°C to uptake the dye.  The neutrophils were then 
centrifuged at 300 x g for 5 min, resuspended in fresh pre-warmed media 
for 30 minutes, washed in RPMI with 10% FBS, and used in experiments.  
Fluorescent labeling is confirmed by florescence microscopy. 
 
2.25 Adoptive Neutrophil Transfer 
 Fluorescent-labeled neutrophils were suspended in Facs buffer at 
1x107 cells/mL.  100 uL of neutrophils were injected i.v. into WT or Fut-/- 
mice.  Mice were sacrificed 24-hours post injection, blood was drawn for 
CBC, and spleen and liver were harvested to assess neutrophil 
accumulation in those organs.  The spleen was disassociated in Facs 
buffer using frosted slides. The cell suspension was then passed through 
a cell strainer and maintained at 4°C.  The liver was minced with sharp 
scissors and incubated in RPMI containing collagenase dispase (Roche) for 
30 minutes at 37°C.  The residual tissue was minced further with a razor 
blade and subjected to another 20 minutes of digestion.  The suspension 
was passed through a 50 um cell strainer to remove debris.   Cell 
suspensions from spleen and liver were then stained with !-Ly-6G, !-
F4/80, and !-CD45 as described above, and analyzed via flow cytometry.   
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2.26 Primary Kupffer Cell Isolation 
 Ten to twelve week old male WT or Fut-/- mice were euthanized, a 
laparotomy was performed, and the IVC was cannulated with a 25-gauge 
butterfly needle.  A perfusion pump was used to infuse perfusion buffer 
(1x HBSS, 2 mM Hepes, 5 mM EGTA; 3 mL/min)[93, 94].  The hepatic 
portal vein was incised to allow full perfusion.  The liver was infused until 
pale yellow in color (45 mL of perfusion buffer), then 50 ml pre-warmed 
digestion solution (1xHBSS, 1.25mg Liberase TM) was infused at a rate of 
3 mL/min.  The liver was carefully removed, and disassociated in DMEM 
with 10% FBS.  The resulting cell suspension contains kupffer cells and 
the larger hepatocytes. The cell suspension was centrifuged at 50 g for 2 
min to pellet the hepatocytes leaving the kupffer cells in suspension[93, 
94].  The Kupffer cells in the supernatant were pelleted at 300 x g for 5 
min.  Isolation purity was assessed via flow cytometric analysis of F4/80+ 
cells, and was usually >80%. 
 
2.27 Bone Marrow Derived Macrophage (BM-MC) and Dendritic Cell (BM-
DC) In Vitro Differentiation 
 BM was isolated as described above.  BM was suspended in RPMI 
with 10% FBS and Pen/Strep in a T75 culture flask for 1 hour.  This 
allowed mature cells to adhere to the plastic. After an hour the non-
! $'!
adherent cells were isolated, pelleted at 300 x g for 5 min, resuspended 
in RPMI with 10% FBS,Pen/strep,10 ng/mL M-CSF (for BM-MCs) or 20 
ng/mL GM-CSF (for BM-DCs), and plated in T75 culture flasks at 37°C 
[20, 27, 28, 46].  After 3 days, 20 mL fresh media was added to both 
cultures.  After 5 days media was removed from BM-MC cultures and 
replaced with fresh differentiation media.  After 7 days both cultures had 
adherent differentiated phagocytes.  Cells were removed from culture 
flasks by incubation with trypsin and re-plated into experimental plates.  
Differentiation was confirmed by flow cytometry for CD11B+ (MC) or 
CD11C+(DCs). 
 
2.28 In Vitro Phagocytic Rate Assay 
 1x105 BM-MC, BM-DC, or primary Kupffer cells (pKCs) were plated 
in a 96-well plate and allowed to adhere for 1 hour at 37°C.  Labeled 
neutrophils were prepared as described above, and incubated at 50°C for 
30 minutes followed by 2 hours at 37°C to induce apoptosis.  1x106 
apoptotic neutrophils were added to each well containing the phagocytes 
and incubated for 1 hour.  Wells were then gently washed to remove un-
engulfed neutrophils.  Phagocytes were harvested with trypsin, washed in 
RPMI, stained with !-Ly-6G, and assessed via flow cytometry. Phagocytes 
that had ingested a labeled neutrophil were Ly-6G-CMFDA+. The 
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percentage of each culture that was positive for ingesting at least one 
neutrophil were calculated, and reported as phagocytic rate.  
 
2.29 In Vitro Efferocytosis assay 
 1x105 BM-MC, BM-DC, or pKCs were plated in a 96-well plate and 
allowed to adhere for 1 hour at 37°C.  Neutrophils were isolated, labeled, 
and apoptosis was induced as described above.  Adherent phagocytes 
were incubated in control media or stimulated with 10ng/mL LPS in RPMI 
with 10% FBS for 4 hours to induce IL-23 production, then incubated with 
1x106 apoptotic neutrophils for 2 hours[17, 27, 34, 35].  Supernatants 
were collected to measure IL-23 production via ELISA, and adherent cells 
were lysed with RLT buffer, and mRNA was isolated as described above. 
 
2.30 DSS-Induced Colitis 
 Colitis severity has been shown to be strongly influenced by the 
microflora. Therefore, because littermate controls are not available for the 
Fut-/-, Rag1-/-, or Rag1-/-/Fut-/- strains, bedding from experimental mice 
was mixed for 7 days before the start of the experiment. Colitis was 
induced by administering 3% DSS in the drinking water of experimental 
mice.  Mice were given fresh DSS or control water every day for 5 days 
followed by regular water for 0, 3, or 5 days.  Mouse weight and fecal 
occult bleeding status were monitored daily.  
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2.31 Preparation of Colon for Histology 
 Following euthanasia, the colon was removed, flushed with cold PBS 
to remove fecal material, and opened longitudinally.  The colon was then 
placed between two pieces of moistened bibulous paper that are fastened 
closed with paper clips, and then fixed in phosphate buffered formalin 
overnight at 4°C.  The tissue was then equilibrated into a 10% sucrose 
solution for 24 hours and 30% sucrose solution for another 24 hours.  It 
was then cut into proximal, middle, and distal thirds, embedded 
individually into OCT freezing compound, and frozen on dry ice.  7 µm 
sections were cut from the tissue block and mounted on slides and 
allowed to dry overnight at RT. 
 
2.32 Hematoxylin and Eosin (H&E) Staining of Tissue Sections 
 Dried slides were placed in distilled water for 3 minutes, and 
stained with Meyers Hematoxylin for 3 minutes.  The slides were then 
washed in distilled water for 5 minutes, dipped in .3% hydrochloric acid in 
ethanol, stained in eosin for 30 seconds, and washed in distilled water for 
5 minutes.  The slides were dehydrated in increasing concentrations of 
ethanol (70% for 2 minutes, 95% for 2 minutes 100% for 2 minutes, and 
xylenes for 5 minutes), cover-slipped with cytoseal,  and allowed to dry 
for 1 hour before imaging.  
! $*!
 
2.33 Histologic Scoring of Colon Sections 
 H&E stained sections were imaged consecutively starting at the 
rectum and continuing proximally to the mid-colon.  Each image was 
scored for disease severity, and all scores are averaged to determine the 
final histologic score for the animal.  Three criteria are scored: 
inflammation severity, inflammation extent, and crypt damage[95].  Each 
category were scored 0 (no disease/change) to 4 (extremely severe).  
Inflammation severity (P1) scores were: 0-No inflammation present, 1-
Mild inflammation, 2-Moderate inflammation, 3-Severe inflammation.  
Inflammation extent (P2) was scored as: 0- None, 1-Mucosa only, 2-
Submucosa and mucosa, 3-Transmural.  Crypt damage (P3) was scored 
as: 0-No change, 1- Crypts are 1/3 above muscularis mucosa (mm), 2- 
Crypts are 2/3 above the mm, 3- Crypts absent but epithelium intact, 4-
Crypts absent and epithelium gone.  If disease severity varies across the 
image the two sections can be scored independently, and the percent 
involvement can be divided between the divergent severities.  The 
percent involvement (I) was scored as: 0-None, 1-25%, 2-50%, 3-75%, 
4-100% of the mucosa in the image.  The scores were then calculated as 
follows (P1xI)+(P2xI)+(P3xI)= Histologic score[95].  
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2.34 Statistical Analysis 
 For two group comparisons, paired two-tailed Student T-Tests were 
performed.  A p value of less than 0.05 was considered significant.  For 
multiple group comparisons an anova was performed with a Tukeys 
multiple comparison post-hoc test.  A p value of less than 0.05 was 
considered significant.  Survival curve significance was determined using 
a Chi square test with p values of less than 0.05 was considered 
significant.  Graphing and statistical analysis was performed using 
Graphpad Prism v6.0e software. 
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Chapter 3 – Results 
 
3.1) Characterization of the Immune Response in Fut-/- Mice. 
3.1.1 Leukocyte Counts 
 Fut-/- mice have been previously shown to have a pronounced 
selectin-dependent leukocyte trafficking deficiency.  By performing a 
complete blood count (CBC), we confirmed reports that Fut-/- mice have a 
leukocytosis (Figure 3.1), comprised of a 12-fold increase in neutrophils, 
4-fold increase in monocytes, and a 1.4-fold increase in lymphocytes in 
circulation compared to WT mice.  These results suggest that in addition 
to a leukocyte trafficking deficiency, Fut-/- mice may have altered 
hematopoiesis.  
 Because Fut-/- mice lack both functional Fut4 and Fut7 we sought to 
determine each enzyme’s contribution to the leukocytosis found in Fut-/- 
mice.  Whole blood CBCs were done on Fut4-/- and Fut7-/- animals and 
compared to WT and Fut-/- mice.  As shown in figure 3.1, Fut4-/- animals 
had near WT levels of neutrophils, monocytes, and lymphocytes, while 
Fut7-/- animals had elevated leukocyte counts compared to WT mice.  The 
leukocytosis in Fut7-/- mice was 20% lower then Fut-/- mice.  These results 
show that when Fut4 is lost, Fut7 is able to almost completely 
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compensate so that only a minimal phenotype is observed.  In contrast 
when Fut7 is lost, Fut4 can only provide minimal compensation, and a 
significant leukocytosis is observed.  This clearly demonstrates that Fut7 
is primarily responsible for fucosylating the glycoproteins responsible for 
the leukocytosis observed in Fut-/- mice.   
 
3.1.2 Fut-Dependent Alterations of Circulating Cytokine Levels 
 We hypothesized that the circulating cytokine profile would be 
altered in Fut-/- mice compared to WT mice due to the increase in 
circulating leukocyte counts and the associated trafficking and homing 
defects.  To assess the immunologic state of the mice, we performed a 
bio-plex multi-analyte cytokine array to measure any Fut-dependent 
alterations in circulating cytokine concentrations. We measured the 
concentrations of Interleukin-1!, -1", -2, -3, -4, -5, -6, -9, -10, -12(p40), 
-12(p70), -13, -17, Eotaxin, G-CSF, GM-CSF, IFN#, KC, MCP-1, MIP-1!, 
MIP-1", RANTES, and TNF! in WT and Fut-/- plasma (Table 3.1).  Table 
(3.2), shows a summary of significant changes observed in untreated Fut-
/- mice.  We observed significant increases in IL-13, IL-17, G-CSF, MCP-1, 
and MIP-1!. Of special note are the increases in IL-17 (2.5-fold) and G-
CSF (5.5-fold) as these factors are thought to play a crucial role in the 
regulation of granulopoiesis. 
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 We also sought to determine the responsiveness of the immune 
system in Fut-/- mice to infectious stimuli (LPS). We stimulated WT and 
Fut-/- mice with LPS (1mg/kg i.p.), and measured plasma cytokine 
concentrations 12 hours post injection using the same bio-plex assay 
described above.  As shown in Table 3.3, IL-1!, IL-1", IL-6, IL-10, IL-17, 
and G-CSF concentrations were elevated compared to WT LPS treated 
mice. In contrast, Eotaxin, MCP-1, MIP-1", and TNF! concentrations were 
decreased compared to WT LPS treated mice.   These results show that 
Fut-/- mice can still initiate an inflammatory response to LPS, however it 
is characterized by the production of more inflammatory cytokines and 
fewer chemotactic factors then WT mice.  
 Results from the bio-plex cytokine assay and the CBCs taken 
together offer interesting insights into the regulation of the immune 
response.  Fut-/- mice have a 4-fold increase in circulating monocytes and 
elevated concentrations of the macrophage chemotactic factors MCP-1 
(CCL2) and MIP-1! (CCL3) which should promote monocyte migration 
into tissues.  Despite the monocytosis in unstimulated Fut-/- mice, 
circulating plasma concentrations of IL-6 and IL-10 (both of which are 
produced by monocytes in copious amounts) were not different from WT 
concentrations.  Following LPS stimulation, Eotaxin, CCL2, and CCL3 fail 
to be produced at WT levels, however proinflammatory cytokine IL-6 and 
anti-inflammatory cytokine IL-10 concentrations are significantly 
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elevated.  These data suggest that there may be an unknown regulatory 
mechanism limiting circulating monocyte cytokine production in 
unstimulated mice, which is overcome by LPS activation.  Additionally, 
the enhanced production of IL-17 and G-CSF in both stimulated and 
unstimulated mice shows that there is increased granulopoietic signaling 
stimuli in Fut-/- mice, which may be at least partially responsible for the 
observed neutrophilia. 
 
3.1.3 Expansion of IL-17-Producing Leukocyte Populations in Fut-/- Mice 
 Interleukin-17 is a proinflammatory cytokine that has been 
implicated in the pathogenesis of autoimmune diseases (multiple 
sclerosis, lupus, etc), immune response to helminth infection, allergy 
(asthma), and even cardiovascular disease (atherosclerosis).  Due to the 
pleiotropic contribution of IL-17 to the pathogenesis of disease, we 
sought to identify the mechanism of enhanced IL-17 production in Fut-/- 
mice.  Flow cytometry was used to analyze, IL-17 production in single cell 
suspensions of mononuclear leukocytes isolated from blood, spleen, or 
lymph nodes of WT or Fut-/- mice.    Mononuclear cells were stimulated 
with PMA/Ionomycin and Brefeldin A for 4 hours, fixed/permeabilized, and 
stained for surface markers of cell lineage, and for intracellular IL-17.  
Figure 3.2A shows a representative histogram of IL-17 staining of WT and 
Fut-/- mononuclear splenocytes. We identified a 19-fold increase in the 
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number of IL-17-producing CD45+ mononuclear splenocytes in Fut-/- mice 
compared to WT mice.  Further analysis (Figure 3.2B) revealed a 10-fold 
increase in Th17 cells (CD3+CD4+IL-17+), a 23-fold increase in Natural 
Killer Tcells (NKT;CD3+DX5+CD1d+IL-17+), a 18-fold increase in #$ Tcells 
(CD3+CD4-#$TCR+ IL-17+), and a 24-fold increase in Innate Lymphoid 
Cells (ILC;CD3-CD4-CD8-Nk1.1-B220-#$TCR-CD45+IL-17+) compared to 
WT mice. These results show a marked expansion of IL-17-producing cell 
types in Fut-/- mice.   
 It is unclear the activity of which fucosyltransferase is primarily 
associated with the regulating IL-17 production.  To determine if the 
expansion of IL-17-producing cells was dependent on the activity of Fut4 
or Fut7, we analyzed the number of IL-17-producing cells in the spleen of 
Fut4-/- or Fut7-/- mice.  As seen in Figure 3.2B, we determined that the 
loss of Fut4 activity only slightly increased the number of IL-17-producing 
cells (Th17 1.2 fold, NKT 2-fold, #$ Tcell 3-fold, ILC 2.5-fold). In contrast, 
the loss Fut7-/- activity resulted in a marked expansion of IL-17-producing 
cells (Th17 7.5-fold, NKT 19-fold, #$ Tcells 15-fold, ILC 20-fold) compared 
to WT mice.   Similar to the CBC data, these data show that processes 
primarily dependent on Fut7 activity are largely responsible for the 
expansion of IL-17-producing cell populations. 
 Based on these data we hypothesized that the loss of Fut4 and Fut7 
activity enhanced IL-17 production as the result of altered intracellular 
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signaling within the IL-17-producing leukocytes.  We isolated mRNA from 
WT, Fut4-/-, Fut7-/-, and Fut-/- splenocytes, converted it to cDNA, and ran 
quantitative polymerase chain reactions (qPCR) to assess gene 
transcription of IL-17, ROR#t, and IL-23.  We found a significant increase 
in IL-17 gene transcription in Fut7-/- (17-fold) and Fut-/- (28-fold) mice 
compared to WT and Fut4-/- mice (Figure 3.3A).  ROR#t levels were also 
elevated in Fut7-/- (6-fold) and Fut-/- (9-fold) mice compared to WT and 
Fut4-/- mice.  Interestingly IL-23 gene expression levels were not 
significantly different among the genotypes tested.   
 Together these results suggest an increase in the signaling for IL-17 
production. However, the changes in mRNA production were similar to the 
changes in cell number we observed.  Thus it is possible that the changes 
in gene expression reflect only the increased IL-17-producing cell 
population sizes.  Therefore, we performed an in vitro Tcell differentiation 
assay.  We isolated naïve CD4 Tcells from WT and Fut-/- mice with 95% 
purity by negatively selecting CD4 Tcells using magnetic beads.  The 
naïve Tcells were then incubated for five days with IL-23, TGF", and IL-6 
to differentiate the cells into a Th17 phenotype.   At the end of the five 
day incubation period, the Tcells were harvested, stimulated with 
PMA/Ion with Brefeldin A, and stained for intracellular IL-17.  Figure 3.3B, 
shows that under controlled in vitro conditions an equal percentage of 
Tcells became Th17 cells from WT and Fut-/- mice.  These results 
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demonstrated that in vitro the signaling and differentiation pathways for 
IL-17 producing Tcells were not altered by the loss of FUT4 and FUT7.  
This suggests that in vivo the increased prevalence of IL-17 producing 
cells in Fut-/- mice is not the result altered Th17 differentiation, but rather 
an increase in polarizing conditions such as IL-23, TGF", and IL-6.  
Together these results suggest that the intracellular signaling pathways 
regulating the production of IL-17 are unaltered in Fut-/- mice.  We 
therefore hypothesized that the increase in IL-17 production and IL-17-
producing cell populations were related to the leukocyte trafficking 
deficiency. 
 
3.1.4 Fut-Dependent IL-17 expansion and Neutrophilia are Selectin-
Dependent 
 Fut4 and Fut7 are known to fucosylate the selectin ligands. 
However, it is reasonable to consider that they may fucosylate additional 
glycoproteins that express similar underlying glycan structures, especially 
Fut4 that is expressed in a wider variety of cell types.  Experiments were 
performed to determine whether the leukocytosis and cytokine alterations 
required Fut-dependent selectin ligand activity.  To test our hypothesis 
that the leukocytosis and IL-17 phenotypes resulted from the loss of 
selectin-dependent trafficking we performed CBCs and flow cytometric 
analysis of IL-17-producing cell populations in WT, Fut-/-, P-selectin 
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Glycoprotein Ligand-1 (PSGL-1) -/-, P-selectin-/-, E-selectin-/-, L-selectin-/-, 
or ELP-selectin-/- mice.  Results from the individual selectin-deficient mice 
can be compared to the results Fut-/- and ELP-/- mice to determine which, 
if any, of the selectins contribute to the leukocytosis and IL-17 
phenotypes.  As shown in Figure 3.4A, PSGL-1-/-, P-sel-/-, E-sel-/-, and L-
sel-/- mice all had normal circulating leukocyte counts.  The ELP-/- mice 
however, completely recapitulated the leukocytosis observed in Fut-/- 
mice, including the 12-fold increase in granulocytes, 4-fold increase in 
monocytes, and a 1.4-fold increase in lymphocytes.  These results show 
that the leukocytosis observed in Fut-/- mice is selectin dependent. 
 Analysis of the IL-17-producing cell populations in the selectin-
deficient mice showed findings similar to the results of the leukocyte 
counts. PSGL-1-/-, P-sel-/-, E-Sel-/-, and L-sel-/- mice had IL-17-producing 
cell counts of Th17, NKT, #$ Tcells, and ILCs that were similar to counts in 
WT mice.  The cell counts in ELP-/- mice however, recapitulated the 
expansions of Th17, NKT, #$ Tcells and ILC populations seen in Fut-/- mice 
(Figure 3.4B).   
 These experiments strongly suggest that the expansion of IL-17-
producing cells and the neutrophilia observed in Fut-/- mice is dependent 
on the selectin ligand activity afforded primarily by the activity of Fut7.   
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3.2) !(1,3)Fucosyltransferase-Dependent Alteration of 
Granulopoiesis. 
 The previous studies show that the expansion of IL-17-producing 
cells and the neutrophilia observed in Fut-/- mice are selectin dependent.  
We next sought to elucidate how selectin-ligand function can alter 
circulating neutrophil counts and IL-17 production. Based on the studies 
of Stark et al.[20], who proposed a trafficking-dependent regulatory 
feedback loop responsible for maintaining homeostatic granulopoiesis 
(Figure 1.2), we hypothesized that the IL-17-producing cell population 
expansion and neutrophilia were the result of the disruption of neutrophil 
trafficking leading to accelerated granulopoiesis.   
 
3.2.1 In Vivo Manipulation of Granulopoiesis 
 Granulopoiesis is a tightly regulated process that requires constant 
feedback to monitor and maintain neutrophil numbers at steady state 
conditions, while keeping the system primed for rapid neutrophil 
production and release during infection or injury.  Fut-/- mice have a 
leukocyte trafficking deficiency, a marked neutrophilia, and high plasma 
concentrations of IL-17 and G-CSF.  Given these alterations in 
granulopoietic signaling, it was unclear whether Fut-/- animals would be 
capable of responding appropriately to regulatory stimuli for 
granulopoiesis.  Therefore, WT and Fut-/- mice were injected with the 
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neutrophil specific Ly-6G (1A8) antibody to deplete circulating 
neutrophils.  We hypothesized that the clearance of the circulating 
neutrophils would greatly increase efferocytosis–dependent IL-23 
suppression, which would reduce IL-17 and G-CSF production, resulting in 
reduced neutrophil production.  As shown in Figure 3.5A, following the 
injection of 1mg of 1A8, neutrophil counts in WT mice were quickly 
reduced by 90% and required 36 hours to fully recover.  However, 
neutrophil counts remained unaltered in Fut-/- mice following antibody 
injection.  To determine if that the lack of depletion was due to 
insufficient quantities of antibody, we injected 9mg of antibody into Fut-/- 
mice, with no effect on circulating neutrophil counts (Figure 3.5A).   
These results show that normal granulopoietic signals are disrupted in 
Fut-/- mice and suggest the clearance of antibody-labeled neutrophils may 
be a selectin-dependent process.   
 It remained unclear whether emergency granulopoiesis is intact in 
Fut-/- mice.  To test this, we injected WT and Fut-/- mice with 1mg/kg LPS 
and monitored circulating neutrophil counts over 48 hours.  After 12 
hours, neutrophil counts were significantly increased in both WT and Fut-/- 
mice (Figure 3.5B).  The increases in neutrophil counts peaked near 24 
hours for both WT and Fut-/- mice at 50% and 80% of circulating 
leukocytes respectively. By 48 hours, neutrophil counts for WT and Fut-/- 
mice had returned to baseline.  These results clearly show that 
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emergency granulopoiesis is still in tact in Fut-/- mice, indicating that the 
signaling mechanisms involved (TLR, NF-%B, etc.) may be distinct from 
those signaling mechanisms regulating homeostatic granulopoiesis. 
 
3.2.2 !(1,3)Fucosylated Glycans on Myeloid Cells Regulate 
Granulopoiesis. 
 Because the enhanced granulopoiesis is associated with increased 
IL-17 production in Fut-/- mice, I sought to assess the contribution of 
myeloid cells to the enhanced IL-17 production and neutrophilia observed 
in Fut-/- mice. Two novel transgenic mouse lines were utilized: Fut-/-c-
FMS-FUT7-Tg (Tg-Fut) and Fut4-/-c-FMS-CRE-Loxp-FUT7 (Cre-Fut).  As 
shown in the schematic in Figure 3.6A, the Tg-Fut mouse is globally 
deficient in both FUT4 and FUT7, but carries FUT7 transgene driven by 
the myeloid-specific c-FMS promoter.  The result is re-expression of Fut7 
in myeloid cells, allowing them to traffic normally while all other cell 
populations retain a selectin-dependent trafficking deficiency (Table 3.4). 
The Cre-Fut mouse was generated by crossing a Fut4-/- mouse that 
expressed a c-FMS driven Cre recombinase transgene, with a Fut4-/- 
mouse with a floxed FUT7 allele.  The resulting mouse (Cre-Fut) has Cre 
expressed only in myeloid cells.  Once expressed the Cre interacts with 
the Loxp sites to excise the FUT7 gene (Figure 3.6B).  This creates 
Fut4/Fut7 deficient myeloid cells which are unable to utilize selectin-
! &#!
dependent trafficking, while all other leukocyte populations retain Fut7 
expression and can traffic normally (Table 3.4).   
 The genetic manipulations in the Cre-Fut and Tg-Fut mice allow us 
to determine if the neutrophilia and IL-17 alterations are dependent 
exclusively on myeloid cell trafficking.  As shown in Figure 3.6C, Tg-Fut 
mice had normal circulating numbers of neutrophils, monocytes, and 
lymphocytes, while the Cre-Fut mice recapitulated the leukocytosis and 
neutrophilia found in Fut-/- mice.   Flow cytometric analysis of splenic IL-
17-producing cell populations show that Tg-Fut mice have WT numbers of 
Th17, NKT, #$ Tcells, and ILCs, while Cre-Fut mice had a 10-fold increase 
in Th17, a 19-fold increase in NKT, a 16-fold increase in ILC, and a 20-
fold in #$ Tcell counts compared to WT and Tg-Fut mice (Figure 3.6D).  
These results show that myeloid cell trafficking is responsible for the Fut-
dependent alterations in granulopoiesis. 
  
3.2.3 Tcells Are Not Required for Fut-Dependent Alterations in 
Granulopoiesis 
 IL-17 is normally thought to be produced by Tcells (Th17, #$, NKT), 
suggesting we could dampen the exaggerated granulopoietic signaling in 
Fut-/- mice by depleting the Tcell sources of IL-17.  To test this hypothesis 
we crossed Rag1-/- mice, which lack functional B-cells and Tcells, with our 
Fut-/- mice to generate Rag1-/-/Fut-/- mice.  These mice were used to 
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assess the role of B-cells and Tcells in the Fut-dependent granulopoietic 
phenotype.  CBCs were performed on whole blood isolated from WT, Fut-/-
, or Rag1-/-/Fut-/- mice (Figure 3.7).   Rag1-/-/Fut-/- mice retain a 3.5-fold 
increase in circulating leukocytes, a10-fold increase in neutrophils, a 3-
fold increase in monocytes, and have a 9-fold reduction in circulating 
lymphocytes compared to WT mice.  Thus, the Fut-dependent alterations 
in granulopoiesis do not rely on B-cells or Tcells to induce the increased 
neutrophil counts observed in Fut-/- mice.  These data suggest there is a 
nonlymphoid cell that is capable of producing the IL-17 required to 
maintain the neutrophilia in Fut-/- mice. 
 
3.2.4 Bone Marrow-Derived Cells are Responsible for the Neutrophilia and 
IL-17 Expansion in Fut-/- Mice. 
 The results from the Rag1-/-/Fut-/- mouse show that B-cells and 
Tcell are not required to generate the neutrophilia, and may not be 
required for the IL-17-producing cell expansion. However, a myeloid cell 
trafficking deficiency is required to maintain the phenotypes observed in 
Fut-/- mice.  Myeloid cells can reside in peripheral tissues or be derived 
from the bone marrow.  To determine which of these two myeloid 
populations are responsible for the IL-17 expansion and neutrophilia, we 
performed bone marrow transplants (BMTs).   
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 We quickly discovered that Fut-/- mice are more resistant to 
radiation then WT mice.  As shown in Figure 3.8A, after 9gy of radiation, 
100% of WT mice died, while only 20% of Fut-/- mice succumbed.  It is 
interesting to note the studies by Lubberts et al.[96] that show that IL-17 
protected cells from irradiation.  We performed two series of BMT 
experiments.  The first experiment used WT mice irradiated with the 
standard dose of 9gy as recipients of 1x107 cells from WT or Fut-/- BM 
(Figure 3.8A).  The second set of experiments used Fut-/- mice that were 
irradiated with 12gy as recipients of 1x107 cells from WT or Fut-/- BM.  Six 
weeks following BMT, mice were sacrificed and a CBC and analysis of IL-
17-producing cell types were performed.  We observed no difference in 
engraphment of WT or Fut-/- BM into WT recipients (Figure 3.8B).    The 
CBC showed that transfer of WT BM into a WT recipient did not alter 
leukocyte counts, however when Fut-/- BM was transferred into a WT 
mice, a leukocytosis comprised of a 11-fold increase in neutrophils, a 3.8-
fold increase in monocytes, and a 1.3-fold increase in circulating 
lymphocytes was observed (Figure 3.8C).  These results show that the 
neutrophilia in Fut-/- is at least partially dependent on bone marrow 
derived cells.   
 We also quantified the population sizes of IL-17-producing cells in 
WT mice that received WT and Fut-/- BM.  As shown in figure 3.8D, WT 
mice that were reconstituted with WT BM had normal populations of IL-
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17-producing cells.  WT mice that received Fut-/- BM however, had a 7-
fold increase in Th17 cells, a 16-fold increase in NKT cells, a 19-fold 
increase in #$ Tcells, and a 12-fold increase in ILCs.  Taken together, the 
CBC and cell population size data show that the expansion of IL-17-
producing cells and neutrophilia are dependent on bone marrow-derived 
cells.  Together with our results from the Tg-Fut and Cre-Fut mice, these 
data suggest that bone marrow-derived myeloid cell trafficking is 
responsible for the regulation of neutrophil counts and IL-17 production in 
vivo.   
 To determine if bone marrow-derived cells were solely responsible 
for regulating neutrophil counts and IL-17 production, we transplanted 
WT and Fut-/- BM into Fut-/- mice that had been lethally irradiated with 
12gy ionizing radiation.  Transfer of Fut-/- BM into Fut-/- mice had no effect 
on leukocyte counts or population size of IL-17-producing cells (Figure 
3.9B/C).  When WT BM was transferred into Fut-/- mice, circulating 
leukocyte counts dropped to near WT levels.  This was manifest by a 75% 
reduction in circulating leukocytes, an 80% reduction in neutrophil 
counts, a 70% reduction in monocytes, and a 20% reduction in 
lymphocyte counts compared with Fut-/- mice that received Fut-/- BM 
(Figure 3.9B).  The IL-17-producing cell populations were also reduced in 
Fut-/- mice that received WT BM.  We observed an 80% reduction in Th17 
cells, an 88% reduction in NKT cells, a 90% reduction in #$ Tcells, and an 
! &'!
85% reduction in ILCs compared to Fut-/- mice with Fut-/- BM (Figure 
3.9C). 
 The results from the BMT studies show that bone marrow-derived 
cell trafficking is responsible for the expansions of IL-17-producing cells 
and the neutrophilia observed in Fut-/- mice.  Together, these results 
significantly reduce the number of cell types that may be involved in the 
regulation of granulopoiesis to macrophages, dendritic cells, and 
immature neutrophils.  However, additional studies are required to 
identify which specific cell type is responsible for the IL-17-producing cell 
expansion and neutrophilia observed in Fut-/- mice. 
 
3.2.5 Neutrophil Trafficking to Tissue Resident Macrophages Regulates 
Granulopoiesis 
 Our previous experiments (Figures 3.8 & 3.9) determined that Fut-
dependent trafficking of bone marrow derived myeloid cells is responsible 
for the regulation of granulopoiesis, so I next sought to identify the 
specific cell type responsible.   I hypothesized that loss of Fut-dependent 
neutrophil trafficking was responsible for the dysregulation of 
granulopoiesis.  To test this hypothesis I developed an adoptive 
neutrophil transfer protocol.  Neutrophils were isolated from BM of WT 
and Fut-/- mice, labeled with a cell tracker dye (CMPTX-Red or CMFDA-
Green), and injected i.v. into Fut-/- mice (Figure 3.10A).  Mice were 
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sacrificed 24 hours post injection and circulating neutrophil counts and 
neutrophil tissue infiltration was assessed via flow cytometry.   
 As shown in Figure 3.10B, transfer of Fut-/- neutrophils into Fut-/- 
mice, did not alter circulating neutrophil counts.  Transfer of WT 
neutrophils into Fut-/- mice however, reduced circulating neutrophil counts 
by 50%.  Additionally, mononuclear leukocytes were isolated from the 
liver and spleen and analyzed for CFMDA.  A cell that was Ly-6G- CMFDA+ 
was determined to be a phagocyte that had ingested a transferred 
neutrophil.  We found that an equal percentage (23%) of WT and Fut-/- 
labeled neutrophils were phagocytosed in the spleen of Fut-/- mice (Figure 
3.10C).  Interestingly, we found that nearly 8 times as many WT 
neutrophils were cleared by the liver then Fut-/- neutrophils.  These 
findings suggest differential neutrophil trafficking requirements between 
the spleen and liver, and suggest that neutrophil trafficking to the spleen 
is not Fut-dependent.  These results also suggest that neutrophil 
trafficking to the liver is at least partially Fut-dependent, and is 
responsible for regulating homeostatic granulopoiesis. 
 
3.2.6 Fut-/- Phagocytes Have No Defect in Phagocytic Rate, IL-23 
Expression, or IL-23 Production. 
 The results from our previous experiments suggested that 
neutrophil trafficking is required for the maintenance of normal circulating 
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neutrophil counts.  It is possible that loss of Fut4/7 alters tissue resident 
phagocyte function.  Therefore, we assessed the phagocytic function, IL-
23 expression, and IL-23 production in tissue resident or BM-derived 
phagocytes isolated from WT and Fut-/- mice.  The proposed 
granulopoiesis-related functions of bone marrow-derived macrophages 
(BM-MCs) and primary Kupffer cells (pKCs) isolated from WT and Fut-/- 
mice were assessed in vitro.  BM from WT and Fut-/- mice was cultured for 
7 days with M-CSF to differentiate the BM cells into CD11b+ bone 
marrow-derived macrophages (BM-MC).  As shown in figure 3.11A, no 
difference was observed between WT and Fut-/- marrow in the ability to 
differentiate BM cells to BM-MCs.   After confirming that BM-MCs were 
CD11b+ via flow cytometry, BM-MCs were incubated with CMFDA labeled 
neutrophils isolated from WT mice.  After four hours BM-MCs were 
assessed via flow cytometry for CMFDA as a measure of phagocytic rate. 
No difference in phagocytic rate was observed between WT and Fut-/- BM-
MCs, as approximately 70% of CD11b+ BM-MCs from each genotype had 
ingested at least one labeled neutrophil (Figure 3.11B).   
 Granulopoietic regulation is thought to rely heavily on phagocyte IL-
23 production, so IL-23 gene expression and protein production was 
assessed in BM-MCs following LPS stimulation.  As shown in Figure 3.11C, 
there was no difference in IL-23 gene expression or protein production 
! &*!
between WT and Fut-/- BM-MCs.  These results demonstrate that there is 
no overt defect in these granulopoiesis-related functions of Fut-/- BM-MCs. 
 Because the results of the adoptive neutrophil transfer experiments 
suggested that the liver was a major site of neutrophil clearance, we 
isolated pKCs from WT and Fut-/- mice and compared their function.  After 
perfusion and enzymatic digestion of the liver, pKCs were isolated by 
centrifugation, and purity was assessed via F4/80 positivity by flow 
cytometry.  As shown in Figure 3.11D, there was no difference in the 
number of pKCs isolated from WT or Fut-/- livers.  pKCs were then 
incubated with labeled WT neutrophils and phagocytic rate was 
determined via flow cytometry.   No difference was observed in the 
phagocytic rate of pKCs from WT or Fut-/- livers (Figure 3.11E).   Lastly, 
LPS stimulated pKCs were harvested and IL-23 gene expression and 
protein levels were quantified via qPCR and ELISA.  Figure 11F shows that 
there is no difference between IL-23 expression or protein levels between 
WT and Fut-/- mice.  These results suggest that Fut-/- BM-MC and pKCs 
are not deficient in their ability to phagocytose neutrophils, induce IL-23 
expression, or secrete IL-23 protein.   
 
3.2.7 Efferocytosis Does Not Suppress IL-23 Expression or Production 
 IL-23 produced by phagocytes in peripheral tissues is thought to 
maintain granulopoietic signaling.  Phagocyte clearance of apoptotic 
! '+!
neutrophils, called efferocytosis, is thought to suppress IL-23 production 
in phagocytes, dampen granulopoietic signaling, and reduce the number 
of neutrophils being released from the bone marrow.  I hypothesized that 
efferocytosis-dependent IL-23 suppression was reduced in Fut-/- mice due 
to the neutrophil trafficking deficiency, contributing to the increased 
granulopoietic signaling and neutrophilia.  An in vitro efferocytosis assay 
was used to assess the effect of efferocytosis on phagocytes isolated from 
WT or Fut-/- mice.   
 Phagocytes isolated from WT and Fut-/- mice were stimulated with 
LPS to induce IL-23 expression and protein production, then WT apoptotic 
neutrophils were incubated with the phagocytes for four hours.  
Messenger RNA and cell culture supernatants were collected, and IL-23 
was assessed via qPCR and ELISA.  As shown in Figure 3.12A, WT and 
Fut-/- phagocytes induced IL-23 gene expression at equal levels for pKCs, 
BM-MCs, and Bone Marrow Derived Dendritic Cells (BM-DCs).  However, 
after incubation with apoptotic neutrophils, we were unable to detect an 
alteration in IL-23 gene expression.  Similarly, when IL-23 production 
was assessed via ELISA, no difference among WT and Fut-/- pKCs, BM-
MCs, or BM-DCs was observed (Figure 3.12B).   Incubation with apoptotic 
neutrophils had no effect on IL-23 production by WT or Fut-/- pKCs, BM-
MCs, and BM-DCs. 
! '"!
 These results were unexpected. There was no difference between 
WT and Fut-/- efferocytosis, and there was also no detectable alteration in 
IL-23 at the transcript or protein level.  This suggests that either the 
proposed regulatory model of granulopoiesis is incomplete and that an 
additional factor is required to modulate IL-23, or that BM-MCs, BM-DC, 
and pKCs are not involved in maintaining normal granulopoiesis.  
Considering all of the data together, I hypothesize that the model is 
incomplete and that there are additional factors, yet to be discovered that 
contribute to the regulation of granulopoiesis.  
 
3.3) Loss of !(1,3)Fucosylated Glycans Increases the Severity of 
DSS-Induced Colitis 
 Dextran Sodium Sulfate (DSS)-induced colitis is a common model 
of mucosal injury used to model human ulcerative colitis, and in some 
cases Crohn’s disease.  The disease pathogenesis relies heavily on IL-23, 
IL-17, and leukocyte trafficking.  Because of the contrasting phenotypes 
found in Fut-/- mice (proinflammatory elevations in IL-17 and anti-
inflammatory trafficking defect) we wanted to establish whether the loss 
of !(1,3) fucosylation altered the initiation of mucosal injury during DSS 
colitis.  We hypothesized that the enhanced IL-17 production, coupled 
with the pronounced increase in #$ Tcells in Fut-/- mice will cause a more 
rapid and severe colitis than in WT mice.   
! '#!
 To induce disease, 3% DSS was added to the drinking water of WT 
or Fut-/- mice for 5 days, followed by 0, 3, or 5 days of untreated water as 
a recovery period.  Weight and occult rectal bleeding were monitored 
daily.  At the completion of the experiment colons were removed, fixed, 
sectioned, stained with Hematoxylin and Eosin, and scored for disease 
severity. 
 
3.3.1 Ten Day Time Point 
 At the 10 day time point (5 days DSS + 5 days water; as shown in 
figure 3.13A), all WT mice survived and all of the Fut-/- mice died.  Over 
the course of the experiment (Figure 3.13B), Fut-/- mice lost more weight, 
more rapidly, then WT mice.  Unfortunately the demise of the Fut-/- mice 
did not allow us to histologically assess disease severity. 
 
3.3.2 Eight Day Time Point 
 The protocol was shortened to an 8 day experiment (5 days DSS + 
3 days water).  At this time point all the WT and 80% of Fut-/- mice 
survived to the end of the experiment (Figure 3.14A).   By the end of the 
experiment Fut-/- mice lost 10% more weight then WT mice (Figure 
3.14B).  However, when histologic scores were tabulated and compared, 
there was severe disease in both groups with no significant difference 
between WT and Fut-/- mice (Figure 3.14C).  These results were 
! '$!
surprising, as the physical signs of disease had suggested that the Fut-/- 
mice were experiencing more severe disease.  The severe histology 
suggests that an even shorter experiment may be necessary to 
differentiate between groups. 
 Tcells are not thought to play a significant role in the development 
of colitis, however #$ Tcells are the major source of intestinal IL-17 that is 
important for the pathogenesis of colitis. Therefore the Rag1-/- and Rag1-
/-/Fut-/- mice were tested to determine if Tcell trafficking contributes to 
the disease severity observed in Fut-/- mice. Rag1-/- mice had very severe 
colitis, and 50% of Rag-/- mice died before the final time point (Figure 
3.14A) while none of the Rag/Fut-/- mice died.  Both Rag1-/- and Rag1-/-
/Fut-/- mice lost more weight then WT and Fut-/- mice by the end of the 
experiment (Figure 3.14B).   Interestingly, Rag1-/- mice did have 
significantly more severe disease then WT and Fut-/- mice, however the 
Rag1-/-/Fut-/- mice did not have increased disease severity compared to 
WT and Fut-/- (Figure 3.14C). 
 These results suggest that Fut-/- mice have more severe symptoms 
of disease (decreased survival, increased weight loss, increased occult 
rectal bleeding) then WT mice, which was not supported by the histology 
at 8 days.  This could be explained by a possible difference in the rate of 
disease progression.  In addition, the strong increase in disease severity 
of the Rag1-/- mice shows that Tcells and/or Bcells play a protective role 
! '%!
in the pathogenesis of colitis.  The loss of this protection in the Rag1-/-
mice allows for addition inflammation and mucosal damage.  Loss of Fut-
dependent trafficking in the Rag1-/-/Fut-/- mice reduces disease severity, 
suggesting that Fut-dependent recruitment of a non-lymphoid population 
of leukocytes significantly contributes to disease severity. 
 
3.3.3 Five Day Time Point 
 The protocol was shortened to a 5 day experiment (5 days DSS 
treatment).  At this time point all mice survived to the end of the 
experiment.   Fut-/- mice lost 5% more weight then WT mice over the 
course of the experiment (Figure 3.15A).  Histologic scoring of the colitis 
showed that Fut-/- mice had histology score of 17 compared to a score of 
8 in WT mice, indicating that Fut-/- mice have a significantly more severe 
colitis then WT mice (Figure 3.15B).  These data show that loss of !(1,3)-
fucosylation on leukocytes exacerbates mucosal injury in DSS-colitis. 
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Cytokine Fold Change vs. WT 
IL-13 1.6          p=.01 
IL-17 2.5          p=.001 
G-CSF 5.5          p<.0001 
MCP-1 1.4          p=.02 
MIP-1! 1.3          p=.01 
Table 3.2 - Cytokine alterations in unstimulated Fut-/- 
Mice 
Data presented as fold change over WT unstimulated mice 
Data from Table 3.1 
! "#!
!
Cytokine Fold Change vs. WT+LPS 
IL-1! 1.2        p=.01 
IL-1" 1.25      p=.03 
IL-6 4.1        p=.01 
IL-10 1.8        p=.007 
IL-17 2.9        p=.003 
Eotaxin -1.25     p=.003 
G-CSF 2.1        p=.02 
MCP-1 -1.4       p=.05 
MIP-1" -1.4       p=.007 
TNF! -1.2       p=.02 
Table 3.3 - Cytokine alterations in LPS Stimulated Fut-/- 
Mice 
Data presented as fold change over WT LPS stimulated mice 
Data from Table 3.1 
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Genotype Cell Type FUT 4  FUT 7 Trafficking 
Phenotype 
WT Myeloid + + Normal 
Non-Myeloid + + 
Fut-/- Myeloid - - Global Deficiency 
Non-Myeloid - - 
Tg-Fut Myeloid - + Normal Myeloid 
Non-Myeloid - -  
Cre-Fut Myeloid - - Deficient Myeloid 
Non-Myeloid - + 
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Chapter 4 – Discussion and Significance 
 
4.1 Summary of Main Findings 
 The findings outlined in Chapter 3 demonstrate the impact !(1,3)-
fucosylation-dependent selectin-mediated trafficking of leukocytes can 
have on homeostatic immunity, granulopoiesis, and mucosal injury.  
Studies in Chapter 3.1 show that the loss of FUT4 and FUT7 result in a 
leukocytosis characterized primarily by a pronounced neutrophilia.  Fut-/- 
mice also have expanded populations of IL-17-producing Th17, "# Tcell, 
NKT cells, and ILCs compared to WT mice.  I hypothesized that the Fut-
dependent expansion of IL-17 producing cells are the result of altered 
Tcell differentiation, however the results from the in vitro Th17 
differentiation assay suggest that Tcell differentiation is not altered in Fut-
/- mice.  In addition to the alterations in circulating neutrophil counts and 
IL-17-producing Th17, "# Tcells, NKT, and ILCs, circulating concentrations 
of IL-13, IL-17, G-CSF, MCP-1, and MIP-1! are significantly elevated in 
Fut-/- mice compared to WT mice.  All of these findings are primarily 
dependent on FUT7 activity and were shown to be selectin-dependent.   
 Chapter 3.2 assessed the role of !(1,3)-fucosylated glycans in 
regulating granulopoiesis.  Injection of !-Ly-6G into Fut-/- mice failed to 
! "#!
deplete circulating neutrophils. Emergency granulopoiesis signaling 
remains intact, as LPS injection results in significant elevation of 
circulating neutrophil counts in Fut-/- mice.  Studies using the Tg-Fut and 
Cre-Fut mice showed that the neutrophilia and IL-17 production are 
dependent on myeloid cell trafficking.  The identification of elevated IL-17 
production and a marked neutrophilia in Rag1-/-/Fut-/- mice showed that 
B-cells and Tcells are not required for the maintenance of the neutrophilia 
and IL-17-producing leukocyte populations identified in Fut-/- mice.   Bone 
marrow transplantation of Fut-/- BM into lethally irradiated WT mice 
reconstituted the leukocytosis and pronounced neutrophilia and caused 
expansions in IL-17-producing cell populations. Together, these data 
show that BM-derived myeloid cell trafficking is required for maintenance 
of homeostatic granulopoiesis.  These results were confirmed by 
transferring WT BM into lethally irradiated Fut-/- mice, which reconstituted 
WT number of circulating neutrophils and populations IL-17-producing 
cells.  Finally, the results from the adoptive neutrophil transfer 
experiments show that Fut-dependent neutrophil trafficking to the liver in 
part regulates homeostatic granulopoiesis. 
 In Chapter 3.3, the dependence of intestinal injury on !(1,3)-
fucosylation-dependent changes in the inflammatory immune response 
were tested.  Fut-/- mice had more severe disease then WT mice at each 
time point tested in the DSS-induced model colitis. Additionally, at the 8-
! "#!
day time point, Rag1-/- mice developed more severe disease then WT 
mice, however the disease severity was reduced in Rag1-/-/Fut-/- mice.  
 
4.2  Considerations for the Manipulation of Leukocyte Trafficking 
 Leukocyte trafficking has long been known to be a vital process for 
leukocyte maturation, immune surveillance, and response to infection and 
tissue damage.  The findings from our studies reinforce the importance of 
leukocyte trafficking to the maintenance of circulating leukocyte counts 
and IL-17 production, and also offer very interesting insights into the 
effects of manipulating selectin-dependent leukocyte trafficking 
pharmacologically or otherwise.   Our findings demonstrate that inhibition 
of selectin-dependent trafficking stimulates enhanced granulopoiesis and 
increased production of IL-17.  Several pharmacologic compounds are 
available or under development to inhibit selectins in humans[97-99].  
These drugs seek to reduce inflammation, however, our findings suggest 
that their use could result in elevated IL-17 production, which has been 
implicated in autoimmune diseases and IBD.  This raises the potential risk 
of patients developing autoimmune disease or exacerbating other IL-17-
dependent inflammatory disease processes.  Additionally, loss of selectin-
dependent trafficking will cause an increase in granulopoiesis resulting in 
a neutrophilia.  Our findings in a model of colitis indicate that the 
neutrophilia can potentially increase inflammation and tissue injury even 
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in the context of the leukocyte trafficking deficiency.   Fut-/- neutrophils, 
macrophages, and Tcells which require Fut-dependent selectin-mediated 
adhesion events to traffic into tissues, can be isolated from inflamed and 
damaged tissues under disease conditions such as colitis, atherosclerosis, 
and contact hypersensitivity reactions.  The presence of these cells in the 
inflamed tissue suggests that under disease conditions the stringency of 
trafficking requirements into tissues is reduced, potentially due to 
increased vascular permeability or direct damage to the blood vessels. 
While the mechanism of Fut-/- leukocyte entry into disease tissues 
remains unclear, the leukocytes are able to enter the tissues and 
exacerbate immune pathology. 
 While the inhibition of all selectin-mediated leukocyte trafficking in 
Fut-/- or E,P,L-/- mice has severe consequences on circulating leukocyte 
counts and IL-17 production, functional inhibition of only an individual 
selectin (i.e. P-selectin) has much less impact on these effects. The 
results from Chapter 3.1 show that the loss of E-, P-, and L- selectins is 
required to induce a neutrophilia and elevation in IL-17.  Therefore, if a 
particular disease process is dependent on a single selectin, the data 
suggest it would be safe to inhibit that selectin to dampen the 
inflammatory response.  It is important to note that all our experiments 
were conducted in mouse models with a permanent leukocyte trafficking 
deficiency.  Therefore, our results identify systemic changes that occur 
! ""!
after long-term blocking of selectin-dependent leukocyte trafficking.  The 
elevated levels of IL-17 and the neutrophilia resulting from a chronic 
trafficking deficiency reduces the therapeutic potential of long-term 
treatments aimed at inhibiting leukocyte trafficking.  Short-term 
treatments may however, provide an anti-inflammatory effect associated 
with inhibition of leukocyte trafficking without significantly altering IL-17-
producing cell numbers, IL-17concentrations, or circulating neutrophil 
counts. 
 
4.3  Considerations for Our Understanding of the Regulation of 
Granulopoiesis   
 Loss of selectin-dependent leukocyte trafficking inhibits neutrophil 
extravasation, which reduces the clearance of neutrophils by peripheral 
phagocytes, causing accelerated homeostatic granulopoiesis, resulting in 
a pronounced neutrophilia.  The data partially confirm the granulopoietic 
regulatory loop proposed by Stark et al[20]. However they also identify 
additional needed studies.  The results in Chapter 3.2 confirm that 
neutrophil trafficking appears to be required for maintenance of 
homeostatic granulopoiesis.  However, efferocytosis was insufficient to 
suppress IL-23 expression or production in WT or Fut-/- pKCs, BM-MCs, or 
BM-DCs in an in vitro efferocytosis assay. These findings suggest that 
there may be additional factors involved in the modulation of IL-23 
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production.  As our adoptive transfer experiments identified that the liver 
is involved in clearance of neutrophils, we hypothesize that the IL-10 
produced by phagocytes following efferocytosis simulates hepatocytes to 
produce IL-25.  IL-25 has been shown to be a potent inhibitor of IL-23 
production[100-103].  This as yet untested alternate mechanism may 
explain why we were unable to suppress IL-23 in our in vitro efferocytosis 
assay.   
 In addition, our bio-plex data shows that circulating IL-23 levels are 
not elevated in Fut-/- mice under steady-state or LPS-injected conditions.  
The lack of altered circulating IL-23 concentrations suggests that either 
additional cytokines or growth factors may be involved in the proliferation 
of IL-17 producing cell populations or that local IL-23 concentration 
changes can regulate granulopoiesis without affecting systemic circulating 
IL-23 concentrations.  Taken together, these findings demonstrate that 
the model of granulopoiesis regulation proposed by Stark et al., is 
incomplete.  We propose an updated model (Figure 4.1) for the regulation 
of granulopoiesis.  This model reflects the observations we have made 
and highlights areas within the regulatory loop in need of further 
research.  Specifically, 1) the precise stimulus responsible for inducing 
macrophage IL-23 production needs to be elucidated, 2) the additional 
cytokine or growth factors involved in the proliferation of IL-17-producing 
cells need to be determined, and 3) the intracellular signaling events 
! "#!
activated by efferocytosis and responsible for IL-10 production need to be 
studied.  
 Recent studies determined that TRM are distinct populations of 
phagocytes that infiltrate into tissues during embryonic development, and 
that are maintained independent from the BM through adulthood[5, 70, 
72, 78].  The trafficking requirements for TRM progenitors have not been 
studied.  Our findings demonstrate that similar numbers of pKCs can be 
isolated from the liver of WT and Fut-/- mice.   These results suggest that 
the trafficking of fetal hematopoietic progenitors responsible for 
establishing Kupffer cell populations is not dependent on selectin-ligand 
function.   
 While the role for selectins in macrophage phagocytosis, 
efferocytosis, and IL-23 production have not been described, our findings 
demonstrate that macrophages from Fut-/- mice do not have a defect in 
phagocytic rate, IL-23 gene expression, or IL-23 production.  These 
results show that recognition and phagocytosis of apoptotic neutrophils is 
independent of fucosylation-dependent selectin ligand activity, and likely 
depends on macrophage recognition of phosphatidylserine displayed on 
the outer plasma membrane of apoptotic neutrophils, or another Fut-
independent process. 
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4.4 Considerations for Leukocyte Adhesion Deficiency Type II 
 These results have important implications for patients with 
Leukocyte Adhesion Deficiency II.  LADII patients have a deficiency in the 
enzymes responsible for the production of UDP-fucose, the substrate for 
the fucosyltransferases including Fut4 and Fut7. This deficiency in LADII 
results in a loss of fucosylated glycoproteins including the selectin 
ligands.  LADII patients have a leukocytosis with a pronounced 
neutrophilia[4, 104, 105].  Our results suggest that LADII patients will 
have increased number of IL-17-producing Th17, !" Tcell, NKT, and ILCs, 
increased circulating IL-17 and G-CSF concentrations, and accelerated 
granulopoiesis.  These alterations create an altered immune environment 
that may predispose LADII patients to disease.  Specifically, elevated IL-
17 concentrations have been associated with an increased prevalence and 
severity of autoimmune diseases such as multiple sclerosis, psoriasis, 
asthma, and lupus. Despite the fucosylation-dependent leukocyte 
trafficking deficiency, our data suggest that LADII patients will have 
normal populations of TRMs that are fully capable of phagocytosing 
cellular debris and producing cytokines.   
 
4.5 Understanding the Pathogenesis of Mucosal Injury in Colitis 
 Acute DSS-induced colitis is thought to be a granulocyte-dependent 
disease process[85-88, 95].  Therefore, we 
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Fut-/- mice, which have a marked granulocyte trafficking deficiency had 
more severe colitis then WT mice.  These results suggest that the 
elevations in IL-17 and the higher numbers of circulating neutrophils 
enhanced disease pathogenesis more then the protection afforded by the 
loss of fucosylation-dependent selectin-mediated leukocyte trafficking. 
These experiments are unable to determine whether the IL-17 or the 
neutrophilia is responsible for increased disease severity, or their relative 
contributions to the disease process. 
 Rag1-/- mice develop severe DSS-induced colitis[84-88]. Therefore, 
Bcells and Tcells are not required for the induction of colitis.  In our 
experiments Rag1-/- had more severe colitis then WT or Fut-/- mice 
suggesting that lymphocytes (Bregs and Tregs) may inhibit inflammation 
and reduce disease severity.  However when colitis in Rag1-/-/Fut-/- mice 
was assessed, the disease severity was reduced compared to Rag1-/-, and 
was similar to disease severity in WT and Fut-/- mice at the eight day time 
point. Rag1-/- mice do not have a pronounced neutrophilia or elevated IL-
17 like Fut-/- mice, so these findings are difficult to interpret. Our findings 
suggest that a non-lymphoid inflammatory cell exacerbates the severity 
of colitis in Rag1-/- mice, and that these inflammatory cells rely on 
Fut!dependent selectin-mediated trafficking to enter colon and drive 
inflammation.  This would account for the loss of enhanced disease 
severity in Rag1-/-/Fut-/- mice. 
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